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a b s t r a c t
In recent years, magnetic nanoparticles have been studied due to their potential applications asmagnetic
carriers in biomedical area. Thesematerials have been increasingly exploited as efﬁcient delivery vectors,
leading to opportunities of use as magnetic resonance imaging (MRI) agents, mediators of hyperthermia
cancer treatment and in targeted therapies. Much attention has been also focused on “smart” polymers,
which are able to respond to environmental changes, such as changes in the temperature and pH. In this
context, this article reviews the state-of-the art in stimuli-responsive magnetic systems for biomedicaleywords:
agnetic nanoparticles
erroﬂuid
mart polymers
-vinylcaprolactam
applications. The paper describes different types of stimuli-sensitive systems, mainly temperature- and
pH sensitive polymers, the combination of this characteristic with magnetic properties and, ﬁnally, it
gives an account of their preparation methods. The article also discusses the main in vivo biomedical
applications of such materials. A survey of the recent literature on various stimuli-responsive magnetic
gels in biomedical applications is also included.iomedical
pplications
© 2010 Elsevier B.V. 
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. Introduction
Much effort has been devoted to the synthesis of
rganic/inorganic nanocomposites (Khan et al., 2009; Colard
t al., 2009; Cheung and Bon, 2009; Cao et al., 2010; Nguyen
t al., 2010; Sheibat-Othman and Bourgeat-Lami, 2009) in an
ttempt to exploit new hybrid properties derived from various
omponents. Because of their small size, nanoparticles (NP) offer
nique properties and magnetic nanoparticles (MNP) based on
ron oxide composites or hybrid materials, essentially in the form
f core–shell systems are ﬁnding great interest in the ﬁeld of
iomedical applications (Häfeli et al., 1997; Stanciu et al., 2009;
ong et al., 2008; Thakur et al., 2009; Faraji et al., 2010). The study
f microscopic structure of magnetic materials started around
870 (Arshady, 2001) and left to the production of stable colloidal
ron oxide (ferromagnetic) particles by McKeehan and Elmore
1934).
In this context, the term “nanobiomagnetism” can be deﬁned
s the intersection of nanomagnetism and medicine that focuses
n biological systems and/or process (Leslie-Pelechy et al., 2006).
agnetos can act on objects at a distance and this characteristic
akes them available as medical tools. There are works in the lit-
rature describing the removal of safety pins, bullets and grenade
plinters using magnetos (Luborsky et al., 1965; Douglas et al.,
002). The invention of stronger and smaller permanent magnets
ade possible more delicate applications, such as temporarily ﬁx-
ng prosthesis in dentistry, guiding catheters through the body, and
avigating within the brain (Gillies et al., 1994).
The unique size-dependent properties of magnetic nanoparti-
les lead to a growing study of elaboration of these materials with
nteresting perspectives in current technology and future applica-
ions (Craik, 1995). Nanoscale materials have a special relevance to
iomedical applications due to their size compatibility with cells
10–100m), viruses (20–450nm), proteins (5–50nm) and genes
2nm wide by 10–100nm long). Their sizes are small enough to
ove inside the body without disrupting normal functions and can
ccess spaces inaccessiblebyothermaterials. Cells react in thepres-
nce of these nanomaterials and these reactions can induce cellular
rowth or death (Chen et al., 2008). In this sense, the study of the
rocesses involving magnetic nanoparticles is important in order
o prepare available systems for in vivo applications.
The combination of magnetic nanoparticles with polymers in
rder to obtain colloidal or composite stable systems had attracted
uch interest. A polymer shell can act as compatibilizer interacting
ith the environment and can be supplied with biologically or cat-
lytically active functional sites (Liu et al., 2008). On the other hand,
he magnetic properties of the nanoparticles allow the manipula-
ion of the systems (Schmidt, 2007).
Magnetic biomaterials must present additional characteristics
n comparisonwithmaterials used for other applications. For in vivo
pplications of MNP, three basic prerequisites have to be met: (1)
he surface has to be biocompatible, (2) non-toxic, and (3) the par-
icles must be well-dispersed without forming aggregates. Ideally,
urface modiﬁcation should provide good colloidal stability (Liz-
arzán et al., 1999; Yap et al., 2005), biocompatibility and chemical
unctionality for the potential attachment of biorecognisable lig-
nds. In this sense, it appears reasonable the use of iron oxide
anoparticles as amagnetic core encapsulated in a protective poly-
eric shell. In vitro applications have less strict requirements, but
n techniques involving living cells the effect of the materials on
he sample must be previously studied (Gillies et al., 1994).Nowadays, there is an increasing interest on the synthesis of
ew biomaterials produced by polymerization of biocompatible
onomers. Biocompatibility is the capacity of the material to be
ery well tolerated by the body or do not interfere with the normal
ody functions. This characteristic makes these materials availablef Pharmaceutics 403 (2011) 139–161
for in vivo biomedical applications (Macazaga, 2007). In addition
to biocompatibility, materials must be able of being functionalized
with one or more molecules, they must retain their magnetic prop-
erties for a reasonableperiodof time inaqueousmediawithvarying
pH, must not be cleared too quickly from the blood stream, and,
ﬁnally, must form stable, non-aggregating dispersions.
As biocompatible polymers, smart materials are largely studied
for in vivo applications. Stimuli-responsive polymers are macro-
molecules that change their properties in a desiredway responding
to a small change in temperature, pH, electric or magnetic ﬁeld,
among others. This kind of polymers had attracted much attention
in nanomedicine. Thermoresponsive polymers are the most stud-
ied stimuli-responsive polymers due to the fact that this parameter
is directly related with the human body (Konak et al., 2007).
2. “Smart” polymers
Response to stimulus is a basic process of living systems (Jeong
and Gutowska, 2002). It is well known the human body ability to
respond to its environment from the molecular to the macroscopic
level (Nelson, 2008). The functions of living cells are regulated by
macromolecules that respond to changes in local environment and
these biopolymers form the basis around which all major natural
processes are controlled (Alarcón et al., 2005). In this way, stimuli
response is crucial formaintaining normal function aswell as ﬁght-
ing disease. At the molecular level, for example, the body releases
insulin to initiate glycogen formation in response to higher glucose
levels in the blood. At the macroscopic level, the body responds to
external stimuli with a cascade of events, such as when nerve cells
transmit signals to the brain in response to a pain-causing stim-
ulus and subsequently cause muscle contraction (Nelson, 2008).
These examples have inspired scientists to fabricate “smart” mate-
rials that respond to light, pH, temperature, mechanical stress or
molecular stimuli. These responses are manifested as dramatic
changes in one of the following: shape, surface characteristics, sol-
ubility, among others. These polymers are being developed for
uses in ﬁelds such as in medicine, and some speciﬁc examples
range from microﬂuidic devices (Barker et al., 2000) pulsatile drug
release systems (Kikuchi and Okano, 2002) bioadhesion media-
tors (Ista and Lopez, 1998) and motors/actuators (Hoffman et al.,
1999). Responsive polymers are also a major focus in emerging
nanoscale technologies (Kim et al., 2003a,b). Stimuli-responsive
polymers are studied due to the fact that their properties (vis-
coelasticity, transparency, conductivity, etc.) can be controlled by
modifying the structure and organization of the polymer chains
(Wong et al., 2008). This characteristic makes these smart poly-
mers important agents forpharmaceutical delivery systems, among
other applications. Since the macromolecules may be able to self-
organize in aqueous medium, forming predetermined but highly
diversiﬁed structures owing to the multiple types of interactions,
the challenge is to design models of these systems that lead to
the possibility of measuring and controlling the number and the
strength of multi-stimuli-responsive associations. Table 1 provides
some examples of stimuli-responsive polymers. Kinetic and ther-
modynamic control of the stimuli-sensitive response is crucial in all
applications; therefore understanding the structure–property rela-
tionship is essential for further development and rational design of
new functional smart materials (Jeong and Gutowska, 2002).
Electro-responsive polymers can be used to prepare materials
that swell, shrink, or bend in response to an electric ﬁeld (Filipcsei
et al., 2000). These materials have been investigated as a form
of hydrogels to have swelling, shrinking or bending behaviour
in response to an external ﬁeld because this property has been
applied for bio-related applications such as drug delivery sys-
tems, artiﬁcial muscle, or biomimetic actuators (Bawa et al., 2009).
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Table 1
Stimuli-responsive polymers and their corresponding stimulus.
Polymer Abbreviation Type of stimulus Reference
Poly(acrylic acid) PAA pH Kratz et al. (2000)
Poly(acetoacetoxyethyl methacrylate) PAAEM pH Pich et al (2004)
Poly[2-(diisopropylamino)ethyl methacrylate] PDPA pH Peng et al. (2010)
Poly(hexyl methacrylate) PHEMA pH Mahajan et al. (2003)
Poly[2-(dimethylamine)ethyl methacrylate) PDMAEMA pH Liu and Urban (2010)
P4VP pH Liu and Urban (2010)
Poly(dimethylsiloxane) PDMS Electrical ﬁeld Kumar et al. (2007)
Poly[2-(methacryloyloxy)ethyl phosphorylcholine] PMPC Electrical ﬁeld
Poly(ethylenediamine-co-1,10-bis(chloro-carbonyl)decane) Electrical ﬁeld Okahata et al. (1986)
Poly(N-isorpropylacrylamide) PNIPAam Temperature Nakayama et al. (2006)
Poly(N-vinylcaprolactam) PNVCL Temperature
PLA Temperature Motornov et al. (2010)
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choice for a wide range of products (Chen et al., 2008).
There are many different polymers and systems that show ther-
moresponsive behaviour. Table 2 presents LCST values for different
thermoresponsive polymers.
Table 2
Transition temperature of thermoresponsive polymers (cloud point of 1% aqueous
solution) (adapted of Kawaguchi, 1999 and Liu et al., 2009a,b).
Polymer Transition
temperature (◦C)
Poly(N-ethylacrylamide) 72
Poly(N-cyclopropymethacrylamide) 59
Poly(N-methyl-N-ethylacrylamide) 56
Poly(N-acryloylpyrrolidine) 56
Poly(N-ethylmethacrylamide) 50
Poly(N-cyclopropylacrylamide) 45.5
Poly(N-isopropylmethacrylamide) 44
Poly(N,N-diethylacrylamide) 32
Poly(N-isopropylacrylamide) 30.9
Poly(N-vinylcaprolactam) 31Poly(N,N-dimethylacrylamide-co-4-phenyl-azophenyl acrylate)
Poly(N,N-dimethyl acrylamide-co-4-phenyl-azophenyl acrylamide)
Poly(acrylic acid-graft-vinylideneﬂuoride)
lectro-responsive polymers can transform electrical energy into
echanical energy and also have promising applications in biome-
hanics, artiﬁcial muscle actuation, sensing, energy transduction,
ounddampening, chemical separations, and controlleddrugdeliv-
ry, these polymers are an increasingly important class of smart
aterials (Kim et al., 1999).
Light/Photo-responsive polymers are macromolecules that
hange their properties when irradiated with light of the appro-
riate wavelength (Roy et al., 2010). These light-responsive
olymers are supplied with photoactive groups such as azoben-
ene, spirobenzopyran, triphenylmethane or cinnamonyl that can
ndergo reversible structural changesunderUV–vis light by chang-
ng their size and shape, or forming ionic or zwitterionic species
pon irradiation (Motornov et al., 2010). The changes result from
he light-induced structural transformations of speciﬁc functional
roups presented in the polymer backbone or side chains (Lambeth
nd Moore, 2007). Light is a particularly attractive source of energy
or use in biomedical applications. Its intensity and wavelength
an easily be controlled through the use of ﬁlters, and pho-
omasks or lasers allow for fabrication of complex features and
xposure areas with resolution as small as approximately 1m.
he majority of light-responsive chemical moieties are responsive
n the UV spectral range and this property is useful for in vitro
pplications (Katz and Burdick, 2010). Possible applications of pho-
oresponsive polymers include reversible optical storage, polymer
iscosity control, photomechanical transduction and actuation,
ioactivity switching of proteins, tissue engineering, and drug
elivery (Roy et al., 2010). Several light-sensitive particles have
een encapsulated within vesicles that cause a physical change
pon light exposure, leading to vesicle disruption. An important
spect of photo-sensitive polymer systems is that using irradi-
tion as a stimulus is a relatively straightforward, non-invasive
echanism to induce responsive behaviour. These types of poly-
ers have been investigated for many years, but there has been
recent expansion in research to create increasingly complex
acromolecular architectures. Light-sensitive core-shell nanopar-
icles of Au and silica were prepared by Liu and Miyoshi (2008).
hese authors prepared particles with a diameter of approxi-
ately 45nm and a silica shell thickness of within 5nm using
old nanoparticles as templates with 40nm in diameter. The light-
ensitive molecules of vitamin C (Vc), 5(6)-carboxyﬂuorescein-N-
ydroxysuccinimide ester (FLUOS), poly(vinyl alcohol) (PVA), and
,5-dihydroxy-p-benzoquinone (DHBQ) were embedded in silica
hells. 3-aminopropyltrimethoxysilane (APS)wasused tobindwith
old nanoparticle surfaces at different percentages. Silica nanocap-
ules were then prepared using sodium cyanide to dissolve gold
ores. The authors veriﬁed that the silica shells became more
ondense and pore sizes shrunk after light sensitive moleculesLight Kim et al. (2009)
Light Kim et al. (2009)
pH-and ionic strength Järvinen et al. (1998)
decomposed following light irradiationbecause the light-irradiated
nanoparticles dissolved more slowly than the non-light-irradiated
nanoparticles. TEM micrographs revealed that silica nanocapsules
collapsed under high-density electron current.
However, the most important systems, also from a biomedical
point of view, are those sensitive to pH or temperature. Some ther-
moresponsive polymers possess critical temperature close to the
physiological value. Moreover, human body presents variations on
pH along the gastrointestinal tract, and also in some speciﬁc areas
like certain tissues (and tumoral areas) or sub-cellular compart-
ments (Aguilar et al., 2007).
2.1. Thermally-responsive polymers
Thermally-responsive polymers undergo a coil-globule transi-
tion in aqueous solution at temperature values which is known as
lower critical solution temperature (LCST) (Dimitrov et al., 2007).
Aqueous solublepolymers represent adiverse class of polymeric
materials ranging from biopolymers to synthetic systems of enor-
mous commercial utility. These materials have acquired increasing
importance due to the demand for water-based instead of the tra-
ditional solvent-based technological processes. Water, being easily
available and environment friendly, will become the solvent ofPoly(N-n-propylmethacrylamide) 28
Poly(N-methyl-N-isopropylacrylamide) 22.3
Poly(N-n-propylacrylamide) 21.5
Poly(N-methyl-N-n-propylacrylamide) 19.8
Poly(N-acryloylpiperidine) 5.5
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The materials based on reversible supramacromolecular orga-
ization have become increasingly important in recent decades.
hese systems may offer a number of advantages, including lower
rocessing costs due to their reversible properties (Dimitrov et al.,
007).
In the context of thermoresponsive materials, poly(N-
sopropylacrylamide) PNIPAam is the most studied polymer
xhibiting LCST at around 31 ◦C, as shown in Table 2. PNIPAam has
ommonly been referred as a smart material (Fernández-Barbero
t al., 2009).
The phase’s transition of PNIPAam in water is schematically
llustrated in Fig. 1. We can observe that the origin of the “smart”
ehaviour, arises from the entropic gain as water molecules asso-
iated with the amide groups are released when the temperature
s increased above the critical point.
As shown in Fig. 1, at temperatures below the LCST, water acts
s a good solvent for the polymer chains forming hydrogen bonds
ith the amide oxygen. When the temperature is raised above the
CST, polymer-polymer interactions become dominant expelling
ater.
In opposition to the LCST behaviour, some thermoresponsive
olymers possess an upper critical solution temperature (UCST).
hese materials collapsed at temperatures below the UCST and
wells when heated this temperature (Ohnishi et al., 2006).
Although PNIPAam is a thermoresponsive polymer largely used
n the literature, the most of the works describes the synthesis of
his polymer for in vitro applications. The presence of the amide
roups leads to the non biocompatibility of the material and, con-
equently, limits its use for biomedical applications.
In this sense, another example of thermally-sensitive and bio-
ompatible polymer that has been studied for therapeutic purposes
s poly(N-vinylcaprolactam) (PNVCL) (Vihola et al., 2002; Vihola
t al., 2008; ImazandForcada, 2008, 2009; Imazet al., 2008; Iskakov
t al., 2007).Biocompatible thermoresponsive copolymers are also being
eveloped for application in drug delivery and regenerative
edicine. Thermoresponsive copolymers combine two or more
omonomers where at least one of these would give a ther-
oresponsive homopolymer (Liu et al., 2009a,b). They haveransition of PNIPAam (adapted from Dimitrov et al., 2007).
attracted considerable interest in both the polymer and bio-
material literature due to their thermally triggered contraction
and aggregation as well as other potentially useful properties
such as reversible gelation. The LCST can be tuned by the incor-
poration of additional functionality. Several studies have been
performed considering the copolymerisation of NIPAam with
more hydrophilic comonomers. The LCST of copolymers such as
poly(N-isopropylacrylamide-co-2-hydroxyisopropylacrylamide)
(poly(NIPAm-co-HIPAam)) or poly(N-isopropylacrylamide-co-
N-vinylpirrolidone) (poly(NIPAam-co-NVP)), for example, is
higher than that of PNIPAam. Thermoresponsive copolymers
that do not contain N-alkyl substituted polyacrylamides, such
as poly(ethylene oxide) PEO-based copolymers and poly(N-
vinylcaprolactam) PNVCL-based copolymers are also of interest.
PNVCL and PEO-based copolymers are important classes of
biocompatible non-acrylamide-containing thermoresponsive
homopolymers (Verbrugghe et al., 2003).
2.1.1. Thermoresponsive property of poly(N-vinylcaprolactam)
(PNVCL)
Poly(N-vinylcaprolactam) (PNVCL) is known as biocompatible
and suitable for in vivo applications (Maeda et al., 2001a,b). PNVCL
shows LCST inwater close to physiological temperature (35–38 ◦C),
dependingon thepolymer concentration,molecularweight and the
composition in the case of copolymers, which opens perspectives
for applications in biochemistry and medicine (Yanul et al., 2001;
Shtanko et al., 2003). PNVCL is composed of amide group that ren-
der the polymer as a whole hydrophilic (Wallace et al., 2002). It has
a repeat unit consisting of a cyclic amide where the amide group
nitrogen is directly attached to the hydrophobic polymer back-
bone. Thus, unlike the thermo-sensitive poly(N-alkylacrylamides),
it does not produce small amide derivatives upon hydrolysis. This
feature, together with its overall low toxicity, high complexing
ability and good ﬁlm forming properties enables to use in many
medical applications. Up to now, several studies have reported the
phase behaviour of PNVCL in water (Lau and Wu, 1999; Peng and
Wu, 2000; Makhaeva et al., 2003; Lozinskii et al., 2006). Applica-
tions of PNVCL as a biomedical material either in stabilization of
proteases or as a carrier and drug delivery agent, have been previ-
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pig. 2. Effect of the temperature in the appearance of an aqueous solution (5 g/L) of
NVCL.
usly published in the literature (Schmidt, 2007; Kawaguchi, 1999;
üller-Schulte and Schimitz-Rode, 2006). The ﬁrst work with this
onomer had been published in 1968. In this work, Solomon et al.
1968) studied the kinetic of the bulk polymerization of NVCL. In
969, Solomon et al. (1969) studied the kinetic of the polymeriza-
ion of NVCL in toluene. Nowadays, it can be observed an increasing
nterest in the thermoresponsive behaviour of PNVCL, which orig-
nates largely from its biocompatibility and low toxicity (Konak
t al., 2007; Chee et al., 2006). Vihola et al. (2005) studied the
itotoxicity of PNVCL of various molecular weights and the results
evealed that the polymers with molecular weights ranging from
.30×105 gmol−1 to 1.50×106 gmol−1 were well tolerated. How-
ver, for biomedical in vivo applications, the synthesis of PNVCL
ith lower molecular weight is interesting (Inoue et al., 1997). In
ig. 2 we can observe the variation in the appearance of a 5g/L
queous solution of PNVCL with the increase of the temperature at
alues above the LCST.
Below the transition temperature, the PNVCL aqueous solution
s transparentwhile the increase of the temperature above the LCST
s accompanied by the higher turbididity (Fig. 2).
.2. pH-sensitive polymers
.2.1. The pH-sensitive property
pH-sensitive polymers are materials that vary their dimensions
ith the changes in the pHof the surroundingmedia. Thesemateri-
lswill swell or collapse depending on the pHof their environment.
his behaviour is attributed to the presence of certain functional
roups in the polymer chains. There are two kinds of pH sensitive
aterials: one which have acidic group (–COOH, –SO3H) and swelln basic pH (Fig. 3), for example poly(acrylic acid) and another one
hich have basic groups (–NH2) and swell in acidic pH, as chitosan.
he mechanism of response is same for both, just the stimuli vary.
Microgel particles from crosslinked acid segments, for example,
ispersed in water are sensitive to changes in pH of the aqueous
ig. 3. Schematic illustration of the pH-responsive behaviour (below and above the
Ka) of a particulate system constituted by a polymerwith carboxilic acid segments.f Pharmaceutics 403 (2011) 139–161 143
suspension. Increasing the pH causes changes (increase) in the ion-
ization degree of the ionizable polymer. The osmotic pressure due
to the increased ionization will result in swelling of the particles.
The resulting response can be read out as changes of the solu-
tion turbidity. Thus, this responsive behaviour can be described
as a sequence of steps: (i) ionization of the polymer chains; (ii)
swelling of the microgel - changes in the material properties; and
ﬁnally (iii) changing the turbidity of the dispersion–the response.
Obviously, all changes in the microgel particles were related and
resulted in changes of a range of properties and change in turbid-
ity is just an example. Examples of pH-responsive polymers are
macromolecules with acidic or basic functional groups (carboxylic,
phosphoric, or amino functional groups). Changes in pH result in
a shift of chemical equilibrium and in a change of the ionization
degree of the polymer chains (Rühe et al., 2004).
pH-sensitive hydrogels are particularly useful, for example, in
the delivery of drugs or peptides to a speciﬁc site in the gastroin-
testinal tract or in response to small changes in the pH of blood
streamor tissues in a pathological situation, such as a clot or cancer
(Alvarez-Lorenzo and Concheiro, 2002). The range of physiolog-
ical pH is from 1.2 to 7.4, and different body part may have a
special pH surroundings. For example, the stomach possesses pH
1.2 while the pH of the intestine is 7.4. Moreover, it is known
that the extracellular pH of tumours (6.8–6.9) is more acidic than
both tumour intracellular pH (7.2) and normal extracellular tissues
(7.4) (Yan et al., 2007). In this sense, pH sensitive polymers seem
to have high potential application value as drug delivery agents
(Liu et al., 2009a,b). Moreover, it is found that incorporation of a
small amount of pH-sensitive ionisable groups, such as carboxyl
and amino groups, into thermoresponsive polymers can offer a
combination of different stimuli-responsive properties.
2.3. Combination of temperature and pH-responsive properties
There is growing interest in obtaining materials whose aque-
ous solutions and swelling properties can abruptly and reversibly
change in response to simultaneous pH and temperature changes.
The pH- and temperature-sensitive polymer sequences with their
dual function are an example of systems that can respond to a com-
bination of external stimuli. The combination of temperature and
pH-sensitiveproperties in thesamesystemhasbeen targetof great-
est scientiﬁc and technological interest, primarily because these
variables canbechanged in typical biological andchemical systems.
By substituting either weakly ionisable cationic or anionic pen-
dant groups onto a polymer backbone, the polymer can be tuned to
respond to either an increase or decrease in the pH. The ability of
the polymer to respond both to temperature and pH offers an addi-
tional control over the polymer phase behaviour (Dimitrov et al.,
2007). Moreover, the presence of groups from pH-responsive seg-
mentsmodiﬁes the hydrophilicity/hydrophobicity balance, leading
to LCST changes. For example, the LCSTs of copolymers increase
rapidly with increasing acrylic acid comonomer contents at all pH
ranges due to its high hydrophibicity (Khan, 2008).
First of all, it is important to determine the extent and to clarify
the mechanism of the combined inﬂuence of pH and temperature
on the properties of aqueous copolymers solutions and hydrogels.
As it is well known, parameters such as LCST, can be modulated
by the incorporation of different amounts of charged monomers.
Below the LCST both temperature and pH-responsive segments
are hydrophilic. Above the LCST, the thermoresponsive polymer
chains will become hydrophobic and thus the system can easily
form aggregates, micelles or particles with thermosensitive core
and pH-sensitive shells, depending on the parameters of the syn-
thesis and the kind of material obtained. Fig. 4 illustrates the
behaviour of a temperature and pH-responsive system. Recently,
N-isopropylacrylamide has been copolymerised with different
144 S.F. Medeiros et al. / International Journal of Pharmaceutics 403 (2011) 139–161
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Tig. 4. Schematic illustration phase transition of thermo-sensitive copolymer with
crylic segments.
onomers in order to modify the LCST of aqueous copolymers
olutions as well their sensitivity (enthalpy factor and transition
idth). When monomers, which originate thermoresponsive poly-
ers, are polymerised with hydrophilic co-monomers, the LCST
f the resulting polymer will shift to higher temperatures while
opolymerization with hydrophobic co-monomers will lead to
orehydrophobic polymers and thus the LCSTwill increase. There-
ore, copolymerizationwithmonomers containing ionisablegroups
s an interesting approach because it makes possible to adjust the
hermosensitivity for temperature values close to the human body
emperature.
The structure conformations change with the variation of both
emperature and pH. Most of the polymers that respond to more
han one stimulus, in particular to temperature and pH, are pre-
ared by random copolymerisations. It is important to know why
he hydrophobic effects or hydrogen bonding are the main factors
esponsible for the LCST behaviour of the thermoresponsive-based
andom copolymers. In this sense, Salgado-Rodríguez et al. (2004)
ynthesized a series of random NIPAam-based copolymers of sim-
lar composition, which could be split into two groups. One group
ad a controlled number of units with a free acid group while the
ther group was methoxy-protected. These experiments were per-
ormed in order to clarify the effect of possible hydrogen bonding
n the LCST behaviour. These authors observed that in case of the
ost studied system, poly(NIPAam-co-AA), the carboxylic groups
an form hydrogen bonds with the amide groups in the PNIPAam
tructure and these bounds lead to additional polymer-polymer
nteraction,makingphase separationbyheating a less endothermic
rocess than in pure PNIPAam since fewer siteswill be available for
he water to bind to the NIPAam units. However, this is true if all
cid units are ionized, whichwill depend on the pKa constant of the
cid. Thus, we can observe that the hydrogen-bonding interactions
epresent an important role in these systems and as a result two
ypes of pH transitions are expected. In the ﬁrst pH range when
he majority of the units are not ionized (low pH); the LCST will
ecrease with an increasing number of acid units. A second pH
ange may also be observed when the majority of the units are
onized (high pH), so that, the LCST will increase with an increasing
umber of acid units.
Bulmus et al. (2000) synthesized copolymers of PNIPAam and
crylic acid (AA) with low molecular weight. The copolymers dis-
layed both temperature and pH-sensitivity over awide and useful
ange of pH and temperatures. The copolymers were bound to
genetically engineered Streptavidin (SAv) at a site speciﬁcally
esigned to resemble the biotin-binding site of the natural SAv.
he authors found that: (1) the decrease of the pH, which causesFig. 5. A schematically illustration of drug administration routes.
the polymer collapse results in blocking biotin binding as well; (2)
the increase of the pH leads to the swelling of the polymer and it
allowsbiotinbinding, and (3) lowering thepHonceagain causes the
collapse of the polymer and results in partial ejection of the biotin.
These actions are relevant to the study of this system as separa-
tion agents, biosensors, diagnostic and targeted delivery of drugs
or chemical agents. The effects of pH and temperature on the biotin
binding and its release can be useful in a variety of separations
anddiagnostic applications andmay also be useful for pH-triggered
drug delivery at speciﬁc sites in humanbodywhere the pH is signif-
icantly below 7.0 such as the stomach, vagina, salivary glands and
within intracellular vesicles such as endosomes and lysosomes.
2.4. Stimuli-responsive polymers in nanobiomedicine as
controlled drug delivery systems
Nanomedicine is deﬁned as the application of nanobiotech-
nology to medicine. Nanobiotechnology is also making important
contributions to personalized medicine through reﬁnement of var-
ious technologies used for diagnostics and therapeutics as well
as interaction among these. Polymeric nanomaterials and devices
provide unique opportunities to advance medicine, especially in
controlled drug delivery strategies.
It is known that the drug concentration levels in the blood
plasma depend on the quantity of drug released from the device
because drug absorption is determined by its solubility in tissues
and availability of local blood ﬂow in tissue. Moreover, there are
three general regions or sites where drugs act in the body, i.e., they
may act away from cells, in the circulation or in tissues spaces
and within the cells. The major routes that are used to deliver
drugs to the body include oral (gastric, enteric, and colonic), injec-
tions, implants, transdermal, mucosal (ophthalmic, nasal, vaginal,
anal, buccal, and sub-lingual) (Hoffman et al., 2007). The con-
ventional administration routes and the controlled drug delivery
are schematically illustrated in Fig. 5. Conventionally, the admin-
istration routes of drugs includes periodic dosages (A) while in
controlled release, polymer systems deliver drugs in the optimum
dosage for long periods (B), thus increasing the efﬁcacy of the drug,
maximizing patient compliance and enhancing the ability to use
highly toxic, poorly soluble or relatively unstable drugs. Even if the
drug concentration in plasma were to remain reasonably constant,
small short-term ﬂuctuation would always be seen due to factors
such as physical activity, emotional stimulation (stress), eating and
sleeping, etc.
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The main advantages of the use of controlled drug delivery
ystems include: (1) sustained constant concentration of therapeu-
ically active compounds in the blood with minimum ﬂuctuations;
2) predictable and reproducible release rates over a long period
f time; (3) protection of bioactive compounds having a very short
alf-life; (4) elimination of side-effects, waste of drug and frequent
osing; (5) optimized therapy and better patient compliance; and
6) solution of the drug stability problem.
Controlled drug delivery as well as many other applications
sing polymers requires complete control over the architecture of
he polymer microstructure, especially when synthesizing materi-
ls such as microspheres, macrogels and nanogels (Liu et al., 2007).
ydrogels are three-dimensional high-molecular weight networks
omposed of a polymer backbone, water and a crosslinking agent,
hich swell in aqueous medium imbibing water into the network
tructure. The administration routes of hydrogel-based formula-
ions include transdermal, oral, nasal or parenteral. Drug delivery
ystems can be classiﬁed according to the mechanism control-
ing the drug release: (1) diffusion-controlled systems, including
embrane systems (reservoir) and monolithic systems (matrix);
2) chemically controlled systems, including biodegradable sys-
ems and Pendent chain systems; (3) solvent-activated systems,
ncluding osmotically controlled systems and swelling-controlled
ystems and ﬁnally (4) modulated-release systems. Most drug
elivery devices act by a combination mechanisms (Bajpai et al.,
008).
Nanoscale polymeric gels or nanogels can be used as drug
elivery vehicles to develop highly selective and effective thera-
eutic and diagnostic modalities. These nanomaterials can travel
hrough the blood stream without sedimentation or blockage of
he microvasculature and can circulate in the body and penetrate
issues such as tumours. In addition, they can be taken up by the
ells through natural means such as endocytosis. Nanoparticles
ave already been used to deliver drugs to target sites for can-
er therapeutics (Gref et al., 1994) or deliver imaging agents for
ancer diagnostics (Lemarchand et al., 2004). These vehicles can be
ngineered to recognize biophysical characteristics that are unique
o the target cells and therefore minimize drug loss and toxicity
ssociatedwith delivery to non-desired tissues (Chung et al., 2007).
Stimuli-responsive polymeric hydrogels do not dissolve in
ater at physiological temperature and pH but exhibit a phase
ransition in response to change in external conditions such as
H, ionic strength, temperature and electric currents are known as
stimuli-responsive” or “smart” gels. Recently, thesematerials have
ttracted increasing attention in many ﬁelds of academic as well
s industrial research due to their wide applications (Okubo and
akagawa, 1994). Their three-dimensional hydrophilic networks
an retain a large amount of water that not only contributes to
heir good blood compatibility but also maintains a certain degree
f structural integrity and elasticity (Li et al., 2006).
As it was mentioned before, in thermally-sensitive poly-
ers, the balance between segment–segment interactions and
egment–solvent intermolecular interactions can be shifted by
emperature changes. The polymer–solvent interactions decrease
pon increasing temperature above the LCST due to the dominat-
ng effect of hydrophobic interactions at an elevated temperature.
oncerning thermoresponsive micro/nanogels, water diffuses into
he hydrogel at temperature below the LCST and, consequently,
he hydrogel swells. Diffusion involves migration of water into
re-existing or dynamically formed spaces among hydrogel chains.
welling of hydrogel involves a larger-scale segmental motion,
esulting, ultimately, in an increase of the separation distance
mong hydrogel chains (Berens and Hopfenberg, 1989). Above the
CST, there are strong intermolecular and/or polymer–polymer
nteractions, such as hydrogen bonds and hydrophobic interac-
ions, which remain in a decrease in the distance among hydrogelf Pharmaceutics 403 (2011) 139–161 145
chains and, consequently, in the collapsed state of the gels (Yoshida
et al., 1994). In the same way, this decrease of the gels volume
leads to a decrease in charge density on the surface of the gel parti-
cles. As result, the zeta potential of the thermoresponsive gels will
change as a function of the temperature. However, the value of the
zeta potential depends on the ions presented on the surface of the
thermally-sensitive gels.
Rahimi et al. (2008) developed temperature sensitive
nanoparticles based on poly(N-isopropylacrylamide-co-
acrylamide-coallylamine) (NIPAam-AAm-AH) via free radical
polymerization. The use of AAm and AH as comonomers aimed
the increase of the LCST, compared with the NIPAam homopoly-
mer and to provide the functionalization with amine groups.
Transmission electron microscopy (TEM) and laser scattering
technology revealed the sizes of the nanoparticles, which was
inversely proportional to the surfactant concentrations. The chem-
ical composition of the nanoparticles was determined with Fourier
transform infrared spectroscopy (FTIR) and nuclear magnetic
resonance (NMR) and conﬁrmed the presence of functional groups
of each monomer. The nanoparticles did not show signiﬁcant cyto-
toxicity activity against human ﬁbroblast cells. Finally, doxorubicin
(DOX) was used in order to investigate the drug release proﬁles of
the NIPAam-AAm-AH nanoparticles at different temperatures and
the results indicated that higher amounts of DOX was released at
41 ◦C compared to that of 37 ◦C and 4 ◦C.
While nanogels based on temperature-responsive polymers are
generally designed to be altered by external stimuli, pH-responsive
polymers can respond to variations in the intracellular or tissue
environment. The pH-dependent swelling behaviour of a nanogel
can be useful not only for drug release, but also for its loading. The
permeability of pH-responsivenanogels increaseswhen they swell,
allowing either the incorporation ofmolecules/nanoparticles or the
release of previously trapped substances (Deka et al., 2010). Thus,
several pH-responsive polymers have been widely used as a con-
trolled drug delivery system. Dandekar et al. (2009) incorporated
curcumin, a natural anti-cancer agent, for the treatment of colon
cancer in pH-sensitive nanoparticles by emulsion-evaporation
technique, aiming to enhance thebioavailability and, consequently,
the required dose of this active agent. Eudragit® S100 was used
in order to aid targeting due to the fact that this polymer dis-
solves at colonic pH, resulting in selective colonic release of the
entrapped drug. The effect of various process parameters on the
particle size distribution and encapsulation efﬁciency was previ-
ously evaluated. The nanoparticles were characterized in terms
of particle size, drug content, DSC studies, and particle morphol-
ogy. The results revealed that spherical particles were obtained
with encapsulation efﬁciency of the curcumin of 72%. MTT assay
in HT-29 cell line demonstrated higher inhibition of the cancer-
ous cells by the nanoparticles, as compared to curcumin alone.
The author attributed this result to the effect of particles size
on the uptake, resulting in reduction of overall dose require-
ment.
However, nowadays the most hydrogels for biomedical
applications are those sensitive to temperature and/or pH.
Polymer–polymer and polymer–solvent interactions show an
abrupt readjustment in small ranges of pH or temperature (Bajpai
et al., 2008). Stimuli-responsive sensitive polymer gels offer poten-
tial economic alternatives to conventional separation processes
for industrial applications (Kucuk and Kuyulu, 2005). Controlled
permeability variations of responsive gels have also been used
to achieve a variety of size- or charge-selective separations. In
order to study the effect of the addition of acid molecules on the
LCST of thermally-sensitive polymers, acrylic acid is the most com-
monly co-monomer employed. However, this ionisable monomer
restricts the thermosensitivity of the copolymer to a limited range
of pH range because at high pH the carboxylic groups are ionized
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fig. 6. Phase variations of the equilibrium swelling states of the temperature and
H-sensitive nanogels (adapted from Asoh et al., 2006).
nd the polymer becomes rather hydrophilic, thus decreasing its
hermosensitivity. This fact can be attributed to the combined abil-
ty of the residual ionic monomer to break the chain sequences
f the thermoresponsive polymer into short uncooperative seg-
ents. Asoh et al. (2006) deﬁned four main transition stages for
he swelling of systems comprising thermo- andpH-sensitive poly-
ers such as hydrogels (Fig. 6).
We can see in Fig. 6 that the ﬁrst stage (A) (temperature
bove the LCST and pH below the pKa of the acid monomer) is
complete-shrinking state; the thermoresponsive polymer net-
orks aredehydratedabove theLCST,whereas the segmentsof acid
onomer are non-ionized. In contrast, there is a stage (D) (temper-
ture below the LCST and pH above the pKa of the monomer acid)
here the thermoresponsive polymer networks are hydrated and
n a full-swelling state because the segments of the acid monomer
re sufﬁciently ionized to hydrate above the pKa. In addition, there
re two intermediate states: in the ﬁrst one (B), the thermorespon-
ive polymer is dehydrated above the LCST but the pH-sensitive
hains are hydrophilic due to the ionized state of carboxyl groups
hile in the second one (C), the thermoresponsive polymer is
ydratedbelow the LCSTbut thepH-sensitive chains arehydropho-
ic due to the non-ionized state of the carboxyl groups.
. Combination of magnetic and stimuli-responsive
roperties
Nanobiomagnetism is the intersection of nanomagnetism and
edicine that focuses on biological systems and/or processes
Leslie-Pelechy et al., 2006). Some hydrogels and nanoparticles
ave been developed to combine ﬁeld and stimuli-responsive
echanisms within a single polymer system (Wong et al., 2008).
agnetic colloids, also known as a ferroﬂuid, are stable dispersions
f nanometer-sized magnetic particles in a suitable carrier solvent
Häfeli et al., 1997). The liquid carrier canbepolarornonpolar. Since
he last decades, when these materials were initially synthesized,
heir technological applications did not stop to increase (Scherer
nd Neto, 2005).
There are several techniques to obtain magnetic materials such
s magnetite as a microcrystaline powder. Among theses tech-
iques, physicalmethods are known to formnanoparticleswithout
ny control in sizes. Thus, researches have been performed in the
ense to obtain good control of the magnetic properties, size dis-
ribution and chemical composition of the nanoparticles (Elaissari,
003).
In order to avoid agglomeration, the magnetic particles must
e coated with a shell of an appropriate material. According to the
oating, the ferroﬂuids can be classiﬁed into two main groups: sur-
acted, if the coating is a surfactant molecule, and ionic (cationicf Pharmaceutics 403 (2011) 139–161
or anionic), if it is an electric shell. In recent years, the design
and development of magnetic nanoparticles have been the focus of
intense fundamental and applied research, with special emphasis
on their unusual properties and promising new possibilities in the
biomedical area (Lacavaet al., 2004).Due to its biocompatibility this
material can ﬁnd applications in biomedicine, such as: (a) cellular
therapy in cell labeling, separation and puriﬁcation (Wilhelm and
Gazeau, 2008); (b) protein immobilization (Liu et al., 2004); (c) con-
trasting enhancement in magnetic resonance imaging (MRI) (Hong
et al., 2008); (d) localized therapeutichyperthermia (Hiergeist et al.,
1999); (e) biosensors (Astalan et al., 2004), etc.
3.1. Magnetic nanoparticles for in vitro applications
For many years, polymer-based particles have been used in
the biomedical ﬁeld such as in vitro biomedical diagnostic (i.e.
immunoassay tests, cells separation and analysis, nucleic acids
concentration) or as solid-phase supports for immobilization of
biomolecules (Hatakeyama et al., 1998). For these in vitro diagnosis
applications, the phase separation is a crucial step and it is usu-
ally achieved by centrifugation, precipitation or ﬁltration. In this
sense,magnetic particles can offer important advantages over clas-
sical polymer-based particles due to the rapid and easy separation
upon applying an external magnetic ﬁeld (Elaissari, 2009). The pio-
neer work in this ﬁeld has been done by Ugelstad et al. (1993) who
reported the preparation of magnetic microspheres with narrow
size distribution and also described their utilization as a support
for biomolecules. The dispersions of magnetic nanoparticles are
attractive in separation applications as they offer high surface area
and can be functionalized to selectively discriminate between dif-
ferent molecular or cellular species. Kondo et al. (1994) prepared
poly(styrene/N-isopropylacrylamide/methacrylic acid) latex parti-
cles containing magnetite by a two-step emulsiﬁer-free emulsion
polymerization. The author investigated the effect of the mag-
netite to monomer weight ration on the colloidal properties of
the particles and they veriﬁed that the hydrodinamic diameter
decreased with increasing the weight ratio. The effect of thermo-
ﬂocculation of the magnetic latex particles on their separation
properties was studied and it was observed that the separation
time of the magnetic particles with higher magnetite content was
shorter. In addiction, they studied the immobilization of bovine
serumalbumin (BSA) on themagnetic latex particles and the puriﬁ-
cation of anti-BSA antibodies it was possible to verify that these
antibodies were successfully puriﬁed from the antiserum by the
BSA-immobilized magnetic latex particles.
In vitro applications of the MNPs aim the detection (magne-
torelaxometry assays) or the separation (magnetic cell separation)
(Safarik and Safarikova, 1999) of biological species like proteins
(Burns et al., 1965; Kouassi and Irudayaraj, 2008), oligonucleotides
(Horák et al., 2001; Krizová et al., 2006) or cells. Magnetic cell
separation can be done using batch or ﬂow processes, depend-
ing on the speciﬁc application. In batch processing, the magnetic
beads and the material to be analyzed are mixed. It is necessary
to know the reaction kinetics to determine the time necessary for
a sufﬁcient amount of binding. A magnet is used to separate the
magnetically targeted cells from the non-targeted cells, as shown
in Fig. 7. The most commonly used materials for cell separations
are micron-sized polymer beads into which a magnetic material
has been embedded.
Another potential application of magnetic particles is the
real-time detection and monitoring of bacterial, viral and other
pathogenic contamination. Integrated structures utilizing nano-
lithography can perform sorting and quantitative analysis in a
single device. The main advantages of these materials include the
low interference, low background signal, no requirement of pre-
treatment, and the fact that they canbe small enough tobeportable.
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oreover, magnetic nanoparticles have the potential to detect
ore than one molecule at the same time.
In the case of the diagnosis of infectious diseases, in order to
btain an early diagnosis, the detection of very low quantities of
athogen within a large sample volume is required. Thus, the diag-
osis should be speciﬁc and sensitive. Nucleic acid concentration is
n efﬁcient way to gain sensitivity. Today, total nucleic acid extrac-
ion from crude biological samples can easily be performed using
ariousmethods (Boometal., 1990;Elaissari et al., 1999). The litera-
ure describes thedevelopment of some fast and automatednucleic
cid extraction processes using silica magnetic beads (Pinto et al.,
007). However, some biological samples as sputum can contain
ery high amounts of non-speciﬁc RNA/DNA which can strongly
ffect the ﬁnal analysis. In this context, an efﬁcient capture (i.e. spe-
iﬁc and at low target concentration) is required and the extraction
f the target nucleic acid can be performed with colloidal particles,
n general on magnetic carriers.
Blood puriﬁcation using magnetic carriers has been also used
o treat autoimmune and inﬂammatory diseases. T4 and T8 cells
n HIV-infected patients have been isolated using magnetic sepa-
ation, thus allowing to study of the effect of different drugs on
peciﬁc types of cells. Isolation of rare cell populations such as
ndothelial cells in blood down to 10 cells/mL has been accom-
lished (Ugelstad et al., 1998).
.2. Magnetic nanoparticles for in vivo applications
The large surface-to-volume ratio of MNPs provides abundant
hemically active sites for biomolecule conjugation, allowing deli-
ate design and engineering of these MNPs for intended functions
uch as long-circulating in the blood stream, target speciﬁcity
o lesion tissue, optical detectability, and therapeutic delivery
Fang and Zhang, 2009). Other biomedical applications of magnetic
anoparticles include drug delivery and magnetic resonance imag-
ng. Fe3+ ions are the most wanted in formation of intracellular
ndmacromolecular biologically activeormagnetic resonance con-
rast materials because of their non-toxicity and their existence in
ature in many tissues. For these in vivo applications, the magnetic
anoparticles needs to exhibit high magnetic saturation. Biocom-
atible and non-toxic magnetic nanoparticles, well-dispersed in
he solvent carrier, have a lot of potential for in vivo applications
n which superparamagnetic particles are of interest because they
o not retain any residual magnetism after removal of a magnetic
eld (Nagy et al., 2008).Fig. 8. Schematic illustration of the amino-dextran coated magnetic nanoparticles.
Coating of colloidal particles with a layer of a different material
in the nanometer scale is an interesting route in order to modify
the surface properties. Due to their liquid properties and sensi-
tivity to an applied magnetic ﬁeld, such materials can deliver an
anticancer drug to a targeted region of the body, such as a tumour
(Zablotskaya et al., 2009). In this sense, we have been interested
in the synthesis of aqueous iron oxide colloids bearing biologically
active organic ligands. For the in vivo applications dextran coat-
ing agent has been used mostly because of its biocompatibility
(Pradhan et al., 2007). Dextran is a component of plasma substi-
tute and has been used in drug transportation for many years (Yu
et al., 2008). The association of a biocompatible natural polymer
such as dextran with functional compounds for adsorption of some
molecules is an interesting task as shown by Mouaziz et al. (2009).
In this work, the authors reported not only the preparation of
amino-dextran containing submicrometer magnetic particles but
they also studied the colloidal properties of the ﬁnal dispersion
as well they evaluated the use of these particles in nucleic acids
extraction. The schematic illustration of the interaction between
the iron oxide particles and amino-dextran molecules is shown
in details in Fig. 8. Yu et al. (2008) studied the biocompatibil-
ity of dextran-coated magnetic ﬂuids as well as the ﬂuid-body
interaction in vivo. The acute toxicity and irritation of the mag-
netic ﬂuid injected into mice subcutaneous tissues were examined.
The authors achieved a lethal dosage only when the magnetic
ﬂuid concentration was equivalent to 4409.61±514.93mg/kg of
the animal. When injected a 30mg/0.3mL dextran-aqueous ﬂuid,
activities of glutamicoxalacetictransaminase (AST) and glutam-
icpyruvictransaminase (ALT) and cell number of mice blood did
not change statistically. The inﬁltration of the magnetic ﬂuid in
subcutaneous tissues was observed and these phenomena almost
disappeared 72h later.With these results, they could conclude that
the dextran-magnetic ﬂuid was tolerable, safe, and biocompatible.
It was also evaluated the biocompatibility of the magnetic particles
using enzymatic nucleic acid ampliﬁcation reaction. The capture of
plasmid DNA was pointed to be effective. Moreover, the ampliﬁca-
tion reactions showed non-inhibition of enzymes activities in the
investigated conditions.
Another promising biologically active ligand is oleic acid.
Zablotskaya et al. (2009) studied the interaction of iron oxide with
oleic acid. The physico-chemical properties, such asmagnetization,
magnetite concentration and particle diameter were investigated.
Magnetic nanoparticles with 11nm in diameter were obtained.
The authors also performed in vitro tests and they observed that
the iron oxide-to-oleic acid molar ratio, varied from 2.6:1 to 4.7:1,
had some effect against human ﬁbrosarcoma and mouse hepatoma
cells. The authors performed tests in vitro using crystal violet col-
oration in order to evaluate the effect of iron oxide concentration
on the nitric oxide (NO) production and they veriﬁed that the mag-
netic ﬂuid with higher content of iron oxide possessed the higher
NO induction ability. NO is known for its effect on a diverse array
of physiologic and pathologic processes (Bredt and Synder, 1994).
Moreover, this gas radical, produced by many cells in the human
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ody, not only controls important functions in tumour progres-
ion, but may have a major inﬂuence on the outcome of cancer
herapies, particularly those that are mediated by increased gen-
ration of reactive oxygen species (oxidative stress) (Hirst and
litney, 1997). A number of studies have described the complex
elationships between iron and NO (Gow and Stamler, 1998; Kagan
t al., 2001). It is known that the NO production by macrophages
epends on the inducible isoform of NO synthase (iNOS) (Nathan
nd Xie, 1994), while iron is required for dimerization and acti-
ation of iNOS (Stuehr, 1999). However, it still remains unclear
hether iron increases or decreases NO production in vivo. Liver
s the main organ for iron storage (Papanastasiou et al., 2000) and
he Kupffer cells, which are macrophages located in the liver lining
he walls of the sinusoids that form part of the reticuloendothelial
ystem (RES), show the ability of expressing iNOS in the presence
f excess iron (Hida et al., 2003). Thus, as suggested by Hida et al.
2003), the increase in the iron concentration appears to stimulate
he NO production by the Kupffer cells cytokines in rats. Finally,
he antitumour action of the iron oxide nanoparticles was demon-
trated in vivo by Zablotskaya et al. (2009) using sarcoma mouse
odel.
For many controlled drug delivery applications, zero order
elease of therapeutics over prolonged period of time is the goal. In
his context, the use of high frequency alternating magnetic ﬁelds
AMF) to actuate magnetic particles is also rapidly emerging as
n important research area in externally controlled drug delivery
ystems (Satarkar and Hilt, 2008). The ﬁrst use of external mag-
etic ﬁelds to achieve pulsatile release from polymer composites
as demonstrated by Kost et al. (1987). These authors observed
n externally controlled insulin release from magnetic composite
f ethylene vinyl acetate by application of low frequency oscillat-
ng magnetic ﬁeld. More recently, Paoli et al. (2006) demonstrated
nhancement in dextran release by application of low frequency
scillating magnetic ﬁeld to magnetic nanocomposites of colla-
en. It is known that the low frequency oscillating magnetic ﬁeld
pplication relies on interactions between magnetic particles and
esultantmechanical deformationof the gel to squeezeout thedrug
Liu et al., 2008). It was recently observed that pulsatile release
rom magnetic nanocomposites of gelatin hydrogels was obtained
y application of high frequency (50–100kHz) magnetic ﬁeld (Hu
t al., 2006), but the applications of AMF in drug delivery systems
till remain unexplored.
Nowadays, cancer therapy is an important and active ﬁeld
f biomedical research given its relevance in the design of new
nti-tumour devices. In this context, polymers-coated magnetic
anoparticles have been intensively studied and can ﬁnd innu-
erous applications in cancer therapy in order to increase the
peciﬁcity of anticancer drugs in cancer cells (Scherer and Neto,
005). In one of these applications, the idea is that polymeric mag-
etic nanoparticles bounded drug are ﬁrstly injected in a cancer
umour and they are kept there during some time (approximately
5min) by a suitably focused magnetic ﬁeld, with very intense
ction. In this case, the amount of drug necessary is much less than
hat would be necessary if it were dispersed in the whole body.
hen the magnetic ﬁeld is turned off one percentage of the drug
ill disperse in the body but, since the total amount is very small,
here will be practically no side effects.
.3. Stimuli-responsive gels encapsulated magnetic nanoparticles
There is a considerable interest inpreparationofparticles,which
an be manipulated in different systems by external stimuli such
s thermal, electric or magnetic ﬁeld. In this context, some hydro-
els and nanoparticles have been developed to combine ﬁeld- and
timuli responsive mechanisms within a single polymer system.
ncorporation of magnetic iron oxides in polymeric particles can bef Pharmaceutics 403 (2011) 139–161
an interesting route for preparation of hybrid particles, which can
provide this interesting feature.
The development of stimuli-responsive gels is often compli-
cated by the fact that structural changes (such as volume changes),
arekinetically restrictedby relatively slowswellinganddeswelling.
Therefore, optimized design of materials for different purposes is
a challenge. In order to accelerate the response rate and to achieve
agitation without contact, new mechanisms, involving magnetic
and electric ﬁelds could be applied and appears to be very promis-
ing.Moreover, for any technical application it is of great importance
to have a quick and reliable control system.
Electric and magnetic ﬁelds are the most practical stimuli with
respect to signal control. Toprovide anenhanced inﬂuenceof exter-
nal ﬁelds on the gel properties, it is necessary to combine solid-like
and ﬂuid-like behaviour. Therefore, new colloidal solutions termed
“complex ﬂuids” based on ferroﬂuids and polymer gels have been
investigated. Since polymer gels contain a substantial amount of
liquid as a swelling agent, it is possible to design ﬁeld-sensitive
gels by using a polymer network swollen in a complex ﬂuid. The
colloidal particles incorporated within the gel, which are charac-
terized by strong adsorptive interactions between solid particles
and polymer chains allow fast response to an external ﬁeld. These
ﬁeld-sensitive gels can be used to construct new types of sen-
sors, microengines, biomimetic energy-transducing devices and
controlled delivery systems.
In general, those systems are characterized by particle size
and particle size distribution, scanning electron microscopy (SEM)
or transmission electron microscopy (TEM), X-ray diffractometry,
density of the charges on the surface of the nanoparticles, thermo-
gravimetric analyses, fourier transform infrared (FTIR), magnetic
properties, dynamic light scattering (DLS), among other tech-
niques.
In the search for amoregenerally applicabledrug targeteddeliv-
ery method for cancer therapy, magnetically controlled targeted
chemotherapy has been proposed (Gupta and Hung, 1994). The
main objectives of this method are to reduce the amount of sys-
temic distribution of the cytotoxic drug, consequently, eliminating
the associated side effects, and to reduce the dosage required by
more efﬁcient, localized targeting of the drug (Chunfu et al., 2004).
When the particles are administered intravenously, external,
high-gradient magnetic ﬁelds are used to concentrate the complex
at a speciﬁc target site within the body. The process of drug local-
ization is based on the competition between forces exerted on the
particles by the blood compartment andmagnetic forces generated
from the magnet, i.e., the applied ﬁeld. When the magnetic forces
exceed the linear blood ﬂow rates in arteries (10 cm/s) or capillar-
ies (0.05 cm/s), the magnetic particles are retained at the target site
and may be internalized by the endothelial cells of the targeted tis-
sue. The drug can be released from the drug/carrier system either
via enzymatic activity or via changes in physiological conditions
such as pH, osmolality, temperature. Once the drug is released it
can be taken up by the tumour cells (Alexiou et al., 2000).
pH and temperature-sensitive polymer sequences with their
dual function are an example of systems that can respond to a
combination of external stimuli in different forms. Talking about
the pH-sensitive behaviour, acrylic acid is one of the most stud-
ied monomer in literature. For poly(acrylic acid), in acidic pH, the
units of the carboxylic monomer are in a non-ionized state. In this
state, the nanoparticles are stable keeping the drug into the par-
ticles. On the other hand, in basic pH, the carboxyl groups are in
an ionized state. Repulsion forces make the swelling of the parti-
cles, promoting the release of the drug andmagnetic nanoparticles.
Concerning the effect of temperature on thermally-sensitive mag-
netic systems, at temperature values below the LCST the particles
are stable keeping the drug. Above the LCST, the presence of strong
attraction forces between the polymeric chains leads to the for-
S.F. Medeiros et al. / International Journal of Pharmaceutics 403 (2011) 139–161 149
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ation of aggregates expelling the active agent inside the polymer
articles (Fig. 9).
The ﬁrst application of thermally-sensitive magnetic particles
or in vivo applications was described by Chen and Su (2001), who
ynthesized core-shell-type latex particles composed of styrene,N-
sopropylacrylamide (NIPAam) and N-acryloxysuccinimide (NAS)
y surfactant-free emulsion polymerisation. The latex particles
evealed thermo-ﬂocculation behaviour due to the presence of
hermally-sensitive segments composed by NIPAam. The authors
nvestigated the immobilization of the enzyme -chymotrypsin
hrough covalent bonding with the reactive ester groups from
AS. Magnetite particles were prepared and incorporated to the
hermally-sensitive latex particles during the polymerisation pro-
edure in order to enhance the sedimentation rate upon the action
f a magnetic ﬁeld, which was reported to be 6 times faster. The
verage hydrodynamic diameters were found to be 250nm and
nzyme activity investigation revealed a tendency to increase of
his parameter with temperature. On the other hand, the latex
ggregation at higher temperature tends to decrease enzyme activ-
ty. Finally, the immobilization system showed a gain of 54.3% in
nzymatic activity, compared with previous studies.
Magnetic carriers were ﬁrst used to target cytotoxic drugs (dox-
rubicin) to sarcoma tumours implanted in rat tails (Widder et al.,
983) as well as to target cytotoxic drugs to brain tumours (Pulfer
t al., 1999). Gaharwar et al. (2009) prepared surface-modiﬁed
anoparticles with a core-shell structure. The core consisted of
agnetic nanoparticles and the shellwas composed of biocompati-
le and biodegradable thermoresponsive hydroxypropyl cellulose.
coupling agent was used in order to bind covalently the core to
he shell. The surface modiﬁcation of the magnetic nanoparticles
as conﬁrmed by X-ray diffractometry and the superparamag-
etic behaviour was observed by magnetization measurements.
he thermoresponsive behaviour of the particles was observed
ith a lower critical solution temperature of 41 ◦C, which is the
ame temperature at which hydroxypropyl cellulose undergoes a
oil-to-globule transition.
Chunfu et al. (2004) prepared a human serum albumin (HSA)-
oated magnetic nanoparticle as a radioisotope carrier labeled
ith 188Re and explored the optimal labeling conditions with
88Re, which is a precondition for further studying the targeting
ehaviour of the particles in vivo. First of all, Fe3O4 nanopar-
icles were prepared by adopting a partial reduction method.
fter, the HSA-coated magnetic nanoparticles were prepared using
microemulsion approach. Finally, the magnetic particles were
abeledwith 188Re. Theyconcluded that themicroemulsionmethod
an be used for the preparation of HSA-coated magnetic particles
ith diameters of about 200nm. Moreover, the particles can be
abeled with 188Re for the purpose of regional target therapy. The
ptimum labeling conditions include: SnCl2-2H2O (8mg/mL), citric
cid (20mg/mL), vitamin C (8mg/mL), reaction volume of 500mL
nd reaction time 3h, with a labeling efﬁciency of about 90%. Thenanoparticles behaviour in temperatures below and above the LCST.
labeled particles are stable up to 72h in BSA, suitable for study
in vivo delivery and can be used for magnetically targeted radio-
therapy.
On theotherhand, Schmidt (2005)hasdevelopedanewstrategy
for thermoresponsive stabilization of magnetic particles by the use
of awell-deﬁnedpolymeric shell. Thermoresponsive ferroﬂuids are
ﬁrst synthesized by combining a magnetic core with a polycapro-
lactone shell showing LCST in DMSO carrier medium. Under the
inﬂuence of a magnetic ﬁeld, the core warms up owing to magnetic
induction and causes a thermal transition in the shell.
Nowadays, cancer is a major social and health issue. Cancer
causes seven million deaths every year, corresponding to 12.5%
of deaths worldwide (WHO website). Different cancer therapy
strategies include combined or separated protocols of surgery,
chemotherapy and radiotherapy. The radiotherapy can be realized
by different forms such as: (1) external beam radiation, (2) arterial
embolization, (3)metabolic radiotherapy, (4) immunoradiothepary
and (5)brachytherapy (Chakarovaet al., 2005;Alevizaki et al., 2006;
Rivera et al., 2006; Andratschke et al., 2007; Hacker and Alken,
2007). Unfortunately, the external radiotherapy destroys nearby
healthy tissue along with the cancer cells resulting in various
side effects or major complications (Buono et al., 2007). There-
fore, recent studies have been performed in the sense to treat
the tumour area by delivering the radioactivity locally. In order
to reduce the mortality rate of conventional radiotherapy and to
enhance treatment effects on malignant tumour, it is highly desir-
able to accurately restrict the radiation to the localized tumour
area (Sun et al., 2000; Hamoudeh et al., 2008). In this sense, much
research has been devoted to the synthesis of magnetic Nan parti-
cles.
Saravanan et al. (2004) studied the use of magnetic gela-
tine micro spheres to promote the controlled release of sodium
diclofenac. They observed that the microspheres contained 8.9%
(w/w) of sodium diclofenac and 28.7% (w/w) of magnetite.
An emulsiﬁcation/cross-linking method was applied using glu-
taraldehyde as croslinker. The formulated microspheres were
characterized by particle size distribution, scanning electron
microscopy (SEM), differential scanning calorimetry (DSC), X-ray
diffraction. The in vivo distribution and target ability of these
gelatin magnetic microspheres after intravenous administration
were studied in rabbits. They veriﬁed that the formulated micro-
spheres were below 5m in size as well the DSC and X-ray
diffractometry revealed the absence of drug-polymer interaction.
Sodium diclofenac was slowly released for more than 18 days.
The application of soniﬁcation as external stimuli to enhance drug
release increased the release rate. The formulated microspheres
were injected intravenously after keeping a suitable magnet near
the target area. However, about 5.5% of injected dose localized near
the target organ.
Wong et al. (2008) described the synthesis, characteriza-
tion and surface modiﬁcation of magnetic nanoparticles and a
1 rnal of Pharmaceutics 403 (2011) 139–161
p
a
m
w
t
t
o
S
n
D
w
s
m
4
m
4
m
(
s
o
e
o
F
F
F
[
k
ﬂ
e
w
l
w
t
t
b
a
a
o
“
f
t
s
e
f
F
c
s
t
s
c
m
b
ﬁ
m50 S.F. Medeiros et al. / International Jou
oly(N-isopropylarylamide) (PNIPAam) microgel, followed by the
ssembly and characterization of magnetic nanoparticles on the
icrogel. To facilitate this deposition, the surface of the microgel
as ﬁrstly modiﬁed via layer-by-layer assembly of polyelec-
rolytes. Inductive heat study revealed that the heat generated by
he magnetic nanoparticles was sufﬁcient to cause the collapse
f the microgel above its volume phase transition temperature.
uccessful conﬁnement of positively and negatively charged mag-
etic nanoparticles between polyelectrolytes layers was achieved.
ynamic light scattering measurements showed that each layer
as successfully deposited and the thermo-sensitivity was pre-
erved in the coated microgel, as there was no detachment of the
agnetic nanoparticles during the phase transition of themicrogel.
. Preparation and properties of stimuli-responsive
agnetic based-materials
.1. Synthesis of iron oxide magnetic nanoparticles
Co-precipitation, as illustratedbelow, is an easy and largelyused
ethod toprepare ironoxidebasednanoparticles, eithermagnetite
Fe3O4) or maghemite (-Fe2O3) from aqueous ferric and ferrous
alt solutions by the addition of a concentrated base solution with
r without heating. The ﬁnal product properties depend on param-
ters such as the ratio between Fe2+ and Fe3+, pH and ionic strength
f the medium, among others.
e2+ + Fe3+ → Fe(OH)2 + Fe2O3·H2O → Fe3O4·H2O
e(OH)2 = FeOH+ +OH−(+HFeO2−)
eOH+ +O2 → [Fe2(OH)3]3+
Fe2(OH)3]3+ + FeOH+ → Fe3O4
In this way, colloidal suspensions of magnetic particles, also
nown as ferroﬂuids, have very interesting properties due to their
uidity and ability to respond to an applied magnetic ﬁeld. How-
ver, they have shown to be not stable and tend to form aggregates,
hich result inhigherparticlesdiameter. The solution for this prob-
em can be found by an adequate coating of the magnetic particles
ith inorganic or organic substances. In this sense, the challenge is
he development of materials that can be used for in vivo applica-
ions.
Magnetic nanoparticles for MRI applications, for example, can
e prepared by adding an alkaline solution (e.g. NH4OH) to ferrous-
nd ferric chlorides in the presence of dextran (poly-d-glucose) or
stabilizing polysaccharide, which is then grafted on the surface
f the core. Usually, ferrous and ferric oxyhydroxides (“green” and
brown” rusts, respectively) are initially formed, and then trans-
ormed into a maghemite (-Fe2O3) or magnetite (Fe3O4) core as
he pH and temperature is further increased. The core can vary
ubstantially in composition and magnetic properties, since sev-
ral different reaction pathways are possible (Elaissari, 2009). The
ormation of different types of iron oxide depends on the initial
e2+/Fe3+ ratio, the type and molecular weight of the polysac-
haride used, and, ﬁnally, on pH and temperature. The control of
ynthesis parameters is necessary in order to avoid the prepara-
ion of extremely polydisperse particles and the requirement of
everal puriﬁcation steps. The post-synthesis steps can include
entrifugation, ultra- and diaﬁltration, column chromatography,
agnetophoresis and soniﬁcation.
Another method used to obtain magnetic nanoparticles is
iomineralization. By using biologic principles to specially con-
ne the synthesis within speciﬁc subunit compartments, novel
aterials with a narrowly deﬁned crystal size can be produced.Fig. 10. X-ray diffraction pattern of Fe3O4 magnetic particles.
In particular, magnetoferritin is of interest for use as an MRI
contrast agent. Its biomineralization is made using the protein
ferritin. Then, ferrous iron is added at high pH and temperature
under strictly anaerobic conditions, resulting in the formation of
a strongly superparamagnetic core. Physicochemical characteriza-
tion of the spherical particles has shown that the iron oxides with
a diameter of about 7.3nm are essentially composed of maghemite
as themineral phase. However, some in vivo studies showed a rapid
biexponential clearance of the magnetoferritin from blood, with a
short initial half-life less than 2min (Ugelstad et al., 1993).
The magnetization measurements of the magnetic particles are
essentially obtained using vibrating sample magnetometer (VSM).
The output is a hysteresis curve, which shows the relationship
between the induced magnetic ﬂux density and the magnetizing
force and gives important information about the magnetic sat-
uration, the remanence, the coercivity and the level of residual
magnetism left in the material.
Fig. 10 illustrates a typical X-ray diffractogram (XRD) of a Fe3O4
nanocrystallite sample. The diffraction peaks are clearly and sharp,
which indicates that the particles are in a good crystal condition.
The peaks could be indexed to (220), (4 00), (4 22), (5 11), (4 40),
and (533) planes of a cubic unit cell, which corresponds to that of
an iron oxide structure. From X-ray diffraction investigation, it is
possible to conﬁrm the good crystallization of Fe2O3 particles.
The superparamagnetic property ofmagneticmicrogel particles
is critical for their application in biomedical and bioengineer-
ing ﬁelds, which prevents magnetic microgels from aggregation
and enables them to redisperse rapidly when the magnetic ﬁeld
is removed (Häfeli et al., 1997). Fig. 11 illustrates the separa-
tion and redispersion process of the oleic acid coated magnetic
nanoparticles. In the absence of an external magnetic ﬁeld, the
dispersion of the MNPs was saddle brown and homogeneous
(Fig. 11A). When the external magnetic ﬁeld was applied, the
MNPs were enriched, leading to transparency of the dispersion
(Fig. 11B).
4.2. Constructing polymer-based magnetic materials
There are different routes to prepare polymer-based mag-
netic nanoparticles. Among these forms the most used are the
polymerization in dispersed media and the magnetic latex par-
ticles from preformed polymers (Elaissari, 2009). The ﬁrst one
includes the classical heterogeneous polymerization processes
such as emulsion, suspension, dispersion, miniemulsion, inverse
emulsion or inverse microemulsion as well some multi-step syn-
thesis procedures. These processes include the polymerization
rnal o
r
n
w
w
p
i
s
o
e
t
b
s
p
t
h
v
d
e
m
s
r
t
p
o
e
i
(
s
m
t
c
w
o
p
e
t
e
p
f
u
d
m
F
a
eS.F. Medeiros et al. / International Jou
eaction in the presence of magnetic particles. The obtained mag-
etic latex nanoparticles can present the following morphologies:
ell deﬁned magnetic core with polymer shell, polymer particles
ith heterogeneous iron oxide nanoparticles distribution in the
olymer matrix and polymer seed bearing magnetic nanoparticles
n the shell. However, in some techniques, such as miniemul-
ion polymerization, polymer particles with heterogeneous iron
xide nanoparticles distribution in the polymer matrix are pref-
rentially obtained. The miniemulsion polymerization process in
he presence of the magnetic nanoparticles as well as the possi-
le morphologies or structures of the obtained nanocomposites is
chematically illustrated in Fig. 12.
On the other hand, magnetic latex particles can be also pre-
ared from preformed polymers. This method involves, in general,
he preparation of emulsions in which the polymer, which can be
ydrophilic or hydrophobic, is dissolved in aqueous or organic sol-
ents according to its properties. Iron oxide ﬁne nanoparticles are
ispersed in the samephase that the polymer and this phase is then
mulsiﬁed in an external continuous phase that can contain a poly-
er as stabilizer, such as poly(vinyl alcohol) (PVA), or a surfactant,
uch as Pluronic®, in order to form an oil in water emulsion. Fig. 13
epresents a schematic illustration of an example of a method used
o obtain this system. The process consists of the utilization of a
reformed polymer and a co-precipitation method.
Hamoudeh and Fessi (2006) have shown the incorporation
f magnetite in poly(-caprolactone)-based microparticles by an
mulsion-solvent evaporation method. One of their most promis-
ng utilization of this material is the magnetic resonance imaging
MRI). In thismethod, the polymer is usually dissolved in anorganic
olvent such as dichloromethane, chloroform or ethyl acetate. The
agnetic particles is dispersed into the preformed polymer solu-
ion and this mixture is then emulsiﬁed into and aqueous solution
ontaining a surfactant/emulsifying agent in order tomake an oil in
ater (O/W) emulsion. After the formation of a stable emulsion, the
rganic solvent is evaporated by increasing the temperature/under
ressure or by continuous stirring (Soppimath et al., 2001). How-
ver, this method is often performed using microencapsulation
echnologyand is not recommended fornanoencapsulation. In gen-
ral, nanocapsules do not resist direct evaporation of the solvent,
ossibly due to the mechanical stress caused by the gas bubbles
ormed inside the aqueous suspension (Mora-Huertas et al., 2010).In this context, anothermethod, including preformed polymers,
sed to prepare magnetic polymeric nanoparticles is the solvent
iffusion process. This method consists of using a partially water-
iscible solvent such as ethyl acetate as an organic solvent. This
ig. 11. Photographs of the separation (A to B) and dispersion (B to A) of the oleic
cid coated magnetic nanoparticles: (A) without external magnetic ﬁeld, (B) with
xternal magnetic ﬁeld.f Pharmaceutics 403 (2011) 139–161 151
solvent can be emulsiﬁed in an aqueous solution of a stabilizing
agent, followed by diluting the internal phase with an excess of
water to induce the precipitation of the polymer.
In general, the established procedures for the preparation of
spherical polymer beads require reaction times between 3 and
4h. However, Müller-Schulte and Schimitz-Rode (2006) developed
a novel inverse suspension polymerization technique that allows
bead preparation within minutes. For this purpose, it is necessary
to ﬁnd appropriate conditions for preparation of stable droplets,
evaluating theoil phase, andparticularly its viscosity andsurfactant
composition. This approach can result not only in a fast synthesis
of the beads but also in a very simple encapsulation of drug model
substances and the necessary magnetic colloids. This technology
provides a broadplatform for a simple, simultaneous encapsulation
of diverse species such as magnetic colloids and bioactive sub-
stances. In addition, it offers a basis for a combinatorial application
of two basic therapeutic procedures and one diagnostic procedure.
Thus, the systems can be used as a contrast agent in tumour tis-
sue imaging and as a drug delivery agent. In magnetically targeted
therapy, a cytotoxic drug is attached to a biocompatible carrier
including magnetic nanoparticles.
For all applications, the control of size, shape and composi-
tion of nanoparticles depends on the type and concentration of
the stabilizers, the Fe2+ and Fe3+ ratio, pH and ionic strength of
the media, among other parameters (Sjogren et al., 1994). The
major problem of such nanoparticles (for in vitro diagnostic) is
related to low magnetic separation under applied magnetic ﬁeld,
due to the Brownian motion compared to magnetic force (Mouaziz
et al., 2009).Then, various roots have been investigated in order
to elaborate large functionalized magnetic particles. The stability
of the magnetic suspensions may be accomplished with micron-
sized or nanometer sized particles (Radbruch et al., 1997). Smaller
nanoparticlesproduce suspensions that are stableagainst sedimen-
tation due to gravity or an applied magnetic ﬁeld, while larger
particles can be used to take advantage of sedimentation as part
of the separation process (Kriz et al., 1998). The particles size
is also important when using magnetic nanoparticles for detec-
tion of biological molecules. This technique is based on changes
in the Brownian relaxation due to binding between the magnetic
nanoparticles and the biologicalmolecules (Chung et al., 2004). The
relaxation frequency of a nanoparticle changes when it binds to
another molecule due to the increase of its hydrodynamic size. The
shift is proportional to the hydrodynamic size of the nanoparticle,
allowing discrimination between target molecules with different
sizes (although molecules with different functionalities, but simi-
lar sizes cannot be independently detected) (Leslie-Pelechy et al.,
2006). The main advantage of this technique is that the signal can
be observed before and after binding, which allows for reliability
checks.
Both in vitro and in vivo biomedical applications usually require
that the nanoparticles have size smaller than 100nm with overall
narrow particle size distribution, so that the particles have uniform
physical and chemical properties. The optimum particle size for
in vivo applications depends on a number of factors, especially for
multi-modal applications such as combined magnetic drug target-
ing and hyperthermia. For in vivo applications, smaller particle size
helps in evasionof the reticulo-endothelial system (RES), thebody’s
immune system responsible for detection and clearance of foreign
particles from circulation (Purushotham et al., 2009). The nanopar-
ticles accumulate due to their speciﬁc size and their extravasation
within the tumour, where themicrovasculature is hyperpermeable
and leaky, a process also aided by the tumour-limited lymphatic
drainage (Gupta and Gupta, 2005). In combination, these factors
lead to the selective accumulation of nanoparticles of sizes gen-
erally between 80 and 200nm in tumour tissue, a phenomenon
known as enhanced permeation and retention (EPR) (Maeda et al.,
152 S.F. Medeiros et al. / International Journal of Pharmaceutics 403 (2011) 139–161
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tig. 12. Schematic representation of the miniemulsion polymerization process in th
btained nanocomposites (a) core(magnetic)-shell, (b) Distribution inside the polym
000). Particles smaller than 10nm are well suited for tumour
enetration, but are rapidly cleared by renal ﬁltration and extrava-
ation. Particles in the size range of 50–150nmare typically cleared
y the Kupffer cells of the liver and those that are larger than
00nm are likely to be ﬁltered by the venous sinuses of the spleen
Neuberger et al., 2005). However, nanoparticles with larger sur-
ace area/volume ratios tend to agglomerate and adsorb plasma
roteins.When the nanoparticles agglomerate, or are coveredwith
dsorbedplasmaproteins, theyarequickly clearedbymacrophages
n the reticulo-endothelial systembefore they can reach target cells
Torchilin andTrubetskoy, 1995). Onepossible approach, therefore,
o increasing thecirculation timeof thesenanoparticles in theblood
tream is to coat the particles with hydrophilic polymers in order
o disperse them and minimize or eliminate the protein adsorption
Florence et al., 1997).
Concerning the in vitro and in vivo applications, the superpara-
agnetic behaviour is also of the magnetic nanoparticles is also of
nterest because they do not retain any magnetism after removal
f magnetic ﬁeld. This parameter is also related with the size of
heparticles. For biomedical applications, particles in the10–50nm
ize range,with appropriate coatings, provide a good balance of cir-
ulation times, ability to be manipulated by an external magnetic
eld and heat generation for hyperthermia. Particles size smaller
han 10nm usually results in lower magnetization of saturation
MS) (Kim and Shima, 2007; Lu et al., 2007) resulting in a decreased
esponse to externally applied magnetic ﬁelds. This increases the
ifﬁculty of targeting tumours deep inside the body. Generation
f large static or alternating magnetic ﬁelds with sufﬁcient pene-
ration depth is then a technical challenge, once it is important to
nsure that the magnetic nanoparticles have the highest MS val-
es possible. Moreover, a successfully magnetic hyperthermia is
lso strongly dependent on MS (Jordan et al., 2001): higher MS val-
es result in higher heating power (for magnetic hyperthermia,
he theoretical ideal magnetic particle core size for heat genera-
ion is in the 10–20nm range). In summary, particles size is an
Fig. 13. Schematic illustration of an example to obtain stisence of magnetic nanoparticles and the possible morphologies or structures of the
atrix and (c) Distribution on the particles surface.
important parameter to be controlled in order to maximize the
power of magnetization at any ﬁeld with superparamagnetism and
to obtain high saturation magnetization values (Chatterjee et al.,
2003). The particles in the appropriate range are rapidly removed
throughextravasations and renal clearance (Pratsinis andVermury,
1996).
Many different polymers have been studied as coating agents
of magnetic particles. However most of these materials can be
only used for in vitro biomedical applications, limiting the use of
these systems. Nanoparticulate systems for in vivo applications
need to improve the pharmacokinetics of drugs including their
rate of adsorption, in situ distribution, metabolism effect, toxic-
ity and their speciﬁc targeting. The in vivo applications of these
materials include the use of the nanoparticles as imaging tools for
in vivonanodiagnosis, liquidperﬂuorcarbons for ultrasonic imaging
and paramagnetic or superparamagnetic contrast agent for mag-
netic resonance imaging (MRI). This last one application is themost
studied in the literature (Häfeli, 2004). Moreover, these nanopar-
ticles can be also used in medicine and biotechnology such as in
hyperthermia, DNA separation, and drug targeting and enzyme
puriﬁcation. In this context, Poly(N-vinylcaprolactam) (PNVCL) is
a promising polymer to be used as coating agent of magnetic par-
ticles due to its biocompatibility and low cytotocixity, besides its
thermoresponsive properties (Vihola et al., 2005). Pich et al. (2004)
described the preparation of hybrid temperature-sensitive micro-
gels, which include magnetite nanoparticles in their structure.
The polymeric microgels were ﬁrstly prepared by surfactant-
free emulsion copolymerizationof acetoacetoxyethylmethacrylate
(AAEM) andN-vinylcaprolactam (NVCL) inwater using 2,2′-azobis-
(2-methylpropyonamidine) dihydrochloride (AMPA) as initiator.
Microgels with a low critical solution temperature (LCST) in water
solutions were obtained. Then, magnetite was deposited directly
into microgels, leading to the formation of composite particles,
which combine both temperature-sensitive and magnetic proper-
ties. The inﬂuence of magnetite load on microgel size, morphology,
muli-responsive polymer with magnetic properties.
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welling–deswelling behaviour, and stability was investigated.
he authors observed that the stability of hybrid microgels was
ot inﬂuenced by the magnetite content and that the obtained
articles were sterically stabilized in aqueous medium by the
ydrophilic biocompatible NVCL-rich shell. They could conclude
hat the obtained results open the door for many applications in
ifferent ﬁelds of material science and technology.
. Applications
With the development of physical and chemical methods of
reparation of colloidal iron oxides, the ﬁrst biomedical applica-
ion of ferroﬂuids also gradually appeared in early 1960s. In 1963
eyers et al. (1963) developed an experimental approach for con-
rolled delivery of magnetic particles in vivo as lymphatic and
ascular contrast and isotopic agent indogs. Four years later, amag-
etic probe for stereotactic thrombosis of intracranial aneurysm
asproposed (Alksne et al., 1967). Then in 1975Turner et al. (1975)
eported the idea of portable liquid helium superconducting mag-
etic for external targeting of iron microspheres (in silicon oil) for
hrombosis of selected arteries, a devicewhichwas later developed
or treatmentofhypernephromas. Thus, anumberofnotable events
n the gradual evolution of biomedical applications of ferroﬂuids
ere succeeded for the utilization of this material for in vitro and
n vivo biomedical applications.
Nowadays,magnetic nanoparticles can be used in awide variety
f biomedical applications. The most promising applications of the
NPs are shown in Fig. 14. Among the in vivo applications, it seemsonvenient to highlight the magnetic resonance imaging (MRI) and
he cancer detection.
In the context of in vivo biomedical applications, an ideal bio-
ompatible stimuli-responsive and magnetic system is able to
ossibility the monitoring, the kinetics and biodistribution of the
ig. 15. Schematic representation of the drug-loaded magnetic nanoparticles localization
rug release.Fig. 14. Biomedical applications of magnetic nanoparticles (adapted from
Nanomedicine © 2009 Future Medicine Ltd).
medication in the organism non-invasively using MRI followed by
the treatment which can be made by different ways such as the
local drug delivery using the sensitive properties of the polymer
and thus, preserving most of the healthy tissues and cells or hyper-
thermia. Fig. 15 illustrates the action of an ideal magnetic system
for in vivo biomedical applications.
As cancer grinding away the lives of a large section of the
society, the importance of nanomedicine is gaining new heights.
Novel nanomedical anticancer therapies with much less pain and
side effects are becoming the ultimate anticancer solutions. The
small size of nanoparticles associated with their properties can
by MRI followed by the treatment of the tumour either by hyperthermia or by the
1 rnal of Pharmaceutics 403 (2011) 139–161
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e very useful in oncology, particularly in imaging. In this con-
ext, iron oxide nanoparticles, when used in combinationwithMRI,
an produce exceptionably sharp images of tumour sites. Another
articularity of magnetic nanoparticles is that they can be encap-
ulated by a functional or a stimuli-responsive polymer and this
ystemcan also contain a speciﬁc drug for cancer therapy that leads
o thepossibility to combinediagnosis and therapeutic applications
n the same system.
.1. Magnetic resonance imaging (MRI)
Developed in 1973 by Paul Lauterbur (1973), magnetic reso-
ance imaging (MRI) has become widely used in hospital, around
he world, since it received the FDA (Food and Drug Adminis-
ration) approval for clinical in 1985 (Häfeli et al., 1997). During
he last decades, many researches have been performed and great
rogress has been achieved in the ﬁeld of pharmaceutical technol-
gy towards the synthesis of sophisticatednanoparticulate systems
or pharmaceutical applications as novel agents for drug delivery
Burns et al., 1985). These systems in general, include materials
anoscale designed, biocompatible and able to degrade into elim-
nable fragments afterdrug release. Sinceoneof themainobjectives
f these materials is to promote controlled and local drug deliv-
ry, the incorporation of a paramagnetic or superparamagnetic
ontrast agent for magnetic resonance imaging has been studied.
RI contrast agents are a unique class of pharmaceuticals that
nhance the image contrast between normal and diseased tissue
nd indicate the status of organ function or blood ﬂow after admin-
stration by increasing the relaxation rates of water protons in
issue in which the agent accumulates (Hong et al., 2008). Para-
agnetic substances have been used as MRI contrast agents due
o their net positive magnetic susceptibility. While superparam-
gnetic and ferromagnetic materials have very large net positive
agnetic susceptibilities when magnetized in the presence of an
xternal magnetic ﬁeld (Nelson and Runge, 1996).
In MRI, image contrast is a result of the different signal inten-
ity produced by each tissue in response to a particular sequence
f applied radiofrequency (RF) pulses. This response is dependent
n the proton density and magnetic relaxation times (Häfeli et al.,
997). Once the proton density of soft tissues has a signiﬁcantly
arrow range throughout the body, natural contrast is mainly
etermined by the relaxation times, which depends on the chem-
cal and molecular structure of the tissue (Koenig, 1996). Tissue
ontrast can bemanipulated by adjusting instrumental parameters
ncluding the applied pulse sequence. The detection of iron can be
mprovedby choosing an imaging sequencewith greater sensitivity
or its relaxation effects.
Many studies have been performed in the sense to explain the
ffect of the paramagnetic or superparamagnetic nanoparticles on
he MRI. Basically, magnetic relaxation is described by the time
onstants T1 (longitudinal) and T2 (transversal). Both relaxations
re exponential and the time constants represent the time for 63%
f the relaxation to take place. If a magnetic ﬁeld B0 is applied,
he absorption of the electromagnetic radiation by the nuclei of
nterest, usually protons, leads to their return or relax to the low-
st energy state of alignment with the applied magnetic ﬁeld. This
s an exponential process and is described by the longitudinal
ime constant T1. The RF pulse also creates a temporary transverse
agnetization that process about B0, inducing a signal in the sur-ounding coil (which is used to generate the MRI image). The signal
ies away quickly because of the dephasing caused by the local
eld, the lack of homogeneity, among other reasons. Thus, due to
hese effects T2 is usually shorter than T1. Then, the signal inten-
ity can be calculated from the T1 and T2 constants according toFig. 16. Schematic representation of the magnetic nanoparticles in vivo detection
using MRI (adapted from Hu et al. (2006)).
Equation (1).
SI = N(1 − e−TR/T1)e−TE/T2 (1)
where N is the proton density and TR is the repetition time used in
the pulse sequence.
In general, tissue or organ-speciﬁc contrast agents consist of
two components: a magnetic label capable of altering the sig-
nal intensity on MR images and a target-group molecule having
a characteristic afﬁnity for a speciﬁc type of cell or receptor
(Hatakeyama et al., 1998). After successful in vitro experiments,
Hu et al. (2006) demonstrated the potential in vivo applications
of a poly(ethylene-glycol) (PEG) (HOOC-PEG-COOH)-coated Fe3O4
nanocrystals conjugated with a cancer-targeting antibody, that is,
the anti-carcinoembryonic antigen (CEA) monoclonal antibody rch
24 (rch 24mAb) for detecting human colon carcinoma xenograft
tumours implanted in nude mice at their proximal thigh region.
Fig. 16 illustrates the use of biocompatible magnetic systems for
in vivo MRI and shows the stages of signal intensity after the injec-
tion of the magnetic material.
We can observe fromFig. 16 that a fraction of the tumour turned
dark as early as 10min after the injection of the rch 24mAb conju-
gates.With time, this fractionof the tumour showinghypo intensity
and becomes darker and bigger until the end of the experiment,
demonstrating a successful binding of Fe3O4 nanocrystals to the
tumour via rch 24mAb. Quantitative analysis revealed a decrease
of the signal intensity in approximately 10%, 24h after injection
(considering the signal intensity equal to100%before the injection).
Magnetic nanoparticles have been also used as a contrast agent
for the reticulo-endothelial system (RES). Clinical applications
include contrast-enhanced imaging of the liver, spleen, and lymph
nodes. However, the particles are also explored as a perfusion
agent. The use of magnetic nanoparticles as imaging of the RES
and perfusion agents presents some advantages. Some of these
advantages are: site-speciﬁc in vivo mapping, cellular tagging and
in vivo transport, in vivo mapping of blood-brain barrier disrup-
tion and development of combined “drug systems” (Ugelstad et al.,
1993). Site-speciﬁc in vivo mapping implies the attachment of site-
speciﬁc molecules, such as sugars and proteins, to the magnetic
nanoparticle. Mapping of the asialoglycoprotein receptor on hepa-
tocytes has beenmadepossible by either attaching arabinogalactan
or asialofetuin to the iron oxide. When the speciﬁc sites are not
directly accessible from the bloodstream, and the magnetic parti-
cles are required to penetrate through the endothelium, small size
and long blood half-life become important factors.
Cellular tagging and in vivo transport mean the use of MRI to
study dynamic cellular processes. For this purpose,MRI needs to be
non-invasive. An example of this study is the use of cellular tagging
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f fetal cells using wheat germ agglutin (WGA)-conjugated mag-
etic particles (Norman et al., 1992) or reconstituted Sendai virus
nveloped containing magnetite (Hawrylak et al., 1993) followed
y cerebral implantation and serial MRI for up to two months. This
ystem allows the monitoring of in vivo cell migration in neural
rafting procedures.
In vivo mapping of blood-brain barrier (bbb) disruption
escribes the easy in vivo detection of systems based on magnetic
anoparticles in the bbb disruption, which is naturally associated
ith some brain lesions. The bbb represents an obstacle for a large
umber of drugs, including antibiotics, antineoplastic agents and
variety of central nervous system (CNS)-active drugs, especially
europeptides. One of the possibilities to overcome this barrier is
drug delivery to the brain using nanoparticles. The nanoparti-
les may be helpful for the treatment of the disseminated and very
ggressive brain tumours (Leslie-Pelechy et al., 2006). An exam-
le of this study consists of the use of MION-46 to demonstrate
esions followingosmoticbbb-disruptions, asdescribedbyNeuwelt
t al. (2008). These authors found that the MION was taken up by
euronal cells in what is thought to be a dextran-speciﬁc process.
he resulting MRI maps correlated well with the histopathological
esults. Thus, it was purposed that MION particles may be applied
s both a diagnostic and therapeutic vector, e.g. a combined drug
ystem.
Coupling in vivo imaging with drug delivery provides perfor-
ance feedback as to the biodistribution and pharmacokinetics of
he vehicle, supplying valuable insight to the formulation scien-
ist seeking to improve vehicle localization or persistence (Norman
t al., 1992). In summary, a combined “drug delivery system” con-
ists of a carrier that contains both a therapeutic and diagnostic
contrast) agent. Following administration or implantation of such
ystem, it could be possible to track medication uptake kinetics
nd biodistribution non-evasively using MRI. Some gels have been
eveloped to track controlled and drug release and transport in
he brain (Reisfeld et al., 1993). For implanted systems, a local
ustained release (with low systemic toxicity) of conjugated dox-
rubicin (Weissleder et al., 1993) and gentamicin (Weissleder et al.,
995) has been evaluated.
.2. Drug delivery
Controlled drug delivery has the potential to improve drug efﬁ-
acy, as well as patient convenience and compliance (Kumar et al.,
007). As the overall drugdosage canbe reducedby50–80%, dosage
t the target site is increased and systemic uptake is decreased.
ocal drug delivery also reduces the patient-to-patient pharma-
okinetic variability inherent in oral and intravenous applications.
rotecting the drugs until they reach their target area increases the
sability of drugs that have a short half-life in the body. Moreover,
he release of a drug over a prolonged period of time maximizes
he effect of drugs such as chemotherapeutics, which are effective
nly during a speciﬁc part of a cell’s life cycle.
Nanoparticles were ﬁrst used for drug delivery around 1970,
ith the development of carriers for vaccines and anticancer drugs,
nd are now widely used and target of intense study (Andratschke
t al., 2007). Nanoparticles for drug delivery must be able to efﬁ-
iently incorporate a reasonably high weight fraction (loading) of
he drug, must form a stable suspension in an aqueous media, must
e biocompatible and biodegradable, and must not be cleared too
apidly from the blood stream. Moreover, they should be able to
e made in a range of sizes, but with uniform size distribution, and
hould be able to be further functionalized. The main attraction of
agnetic nanoparticles from the perspective of drug delivery is the
bility to use the magnetic properties to either limit the drug to a
articular region using magnetic targeting, or to release the drug
emotely.f Pharmaceutics 403 (2011) 139–161 155
These systems can include the encapsulation of the drug
in conjugated to, or adsorbed onto the surface of a nanopar-
ticle. The release may be made via degradation of the carrier
particle or may be triggered by heat or pH. For this purpose,
many drug delivery systems use poly(lactic acid-co-glycolic acid)
(PLGA), poly(-caprolactone) (PCL) and their copolymers, as these
are biodegradable, FDA-approved materials and the degrada-
tion rate can be controlled by the particle formulation (Panyam
and Labhasetwar, 2003). Careful choice of surfactants can allow
hydrophobicdrugs tobe transported throughout thebody. Ionically
bound pharmaceuticals have the advantage that the active-low
molecular weight substances can desorb from the carriers after a
deﬁned time span anddiffuse from the vascularwall into the tissue.
The diffusion through the vascularwall can signiﬁcantly change the
desorption kinetics of the pharmaceutical (Bergemann et al., 1999).
As an example, Epirubicin chemoadsorptively bound to a polymer-
coated particle can desorb according to physiological environment
(pH, osmolarity, and temperature) (Lübbe et al., 1999). The half-life
of the drug desorption can be ﬁxed to be approximately the same
as the desired time for magnetic ﬁeld targeting.
Smartmaterials such as thermally- and pH responsive polymers
are largely studied like carriers for controlled drug delivery. More-
over, as previously seen, a combined drug delivery system which
consists of a carrier that contains both a therapeutic and diagnostic
(contrast) agent is desired.
Magnetic systems are attractive candidates for delivery of high
doses of anticancer drugs in intracavitary therapy (Gupta and
Hung, 1989). There are many studies in literature performed with
the chemotherapeutic anthracycline drugs loaded into magnetic
microcapsules. However, this kind of drugs must be released near
the tumour, and then bind to (or diffuse into) malignant cells in
order to be effective. On the other hand, most of chemotherapeutic
drugs encounter physiologic barriers inmany tumours (Jain, 1991),
andconsequently, parts of the tumourdonot receive sufﬁcientdrug
concentration.
Radioactivity is another factor to be considered which exerts
action over a deﬁned radionuclide-dependent distance and the
resulting radiation penetrates the tissue irrespective of diffusion
barriers, membrane and pressure differences. Beta emitters pen-
etrate up to 10mm in soft tissue, and  emitters up to several
centimeters. In magnetic brachytherapy the radiopharmaceutical
should ideally be distributed as homogenously as possible in the
tumour, and remain thereuntil radioactivity is completelydecayed.
However, it is just possible if the magnetic systems can be targeted
to tumours by planting a magnet in the tumour or in its vicinity,
and holding it there during the decay period.
According to Wootton (1991), magnetic targeting of radio-
labeled microcapsules presents various advantages and can be
achieved as follows:
1. Inject a diagnostic dose of magnetic microcapsules labeled with
a  emitting tracer (for imaging).
2. Apply an adjustable magnetic ﬁeld to target area.
3. Produce an image from the tracer radiationwith gamma camera.
4. Adjust themagneticﬁeld to target themicrocapsules as required.
5. Inject a therapeutic dose of magnetic microcapsules loaded with
the required  (or ) emitter.
6. Apply and maintain the adjusted magnetic ﬁeld for a deﬁned
period.
7. Schütt et al. (1997) performed a similar therapy including an
additional step as follows (either 7a or 7b):
8. Remove the nontrapped radiolabeled magnetic microcapsules
via a blood vessel different from the one used for injection by
means of an extracorporeal magnetic separation.
9. Magnetically conﬁne the microcapsules to target area for a
deﬁned period of time, followed by removal of the (still) radio-
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labeled or drug loaded microcapsules from the body in the same
way as in 7a.
In other words, this last step is similar to the dialysis procedure
n which undesirable substances are removed from the body dur-
ng or after treatment. This study is an example of the possibility
o minimize the undesirable effects of the treatment by magneti-
ally controlling both tumour targeting and removal of unwanted
irculating microcapsules.
Attempted therapeutic use of radiolabeled magnetic microcap-
ules for cancer therapy dates back to 1969, when Mosso and Rand
1973) conceived the ideaof aportable liquidheliumsuperconduct-
ng magnet that could be applied externally to embolize selected
umour feeding arteries by in vivo formed ferrosilicone microcap-
ules.
In vivo evaluation of radiolabeled magnetic microcapsules nor-
ally includes the studyof biodistribution in anappropriate animal
odel, target tissue andwhole body toxicity, treatmentparameters
radiation dose, strength and duration of magnetic ﬁeld), and mon-
toring interventions. In all cases, biocompatibility and toxicity are
arameters hardly discussed.
.3. Chemotherapy
One of the numerous applications of MNP in medicine is the
ancer treatment (Alexiou et al., 2006). Cancer is the second cause
f death in the developed world, killing over 500,000 people in the
nited States in 2000 (Zhang et al., 2004). Chemotherapy is a major
herapeutic approach for the treatment of localized and metasta-
ized cancers. The cancer detection is one of the major goals in
odern diagnostics because early detection and accurate staging
f the primary tumour is a prerequisite for or successful cancer
herapy. Effective cancer treatment is based on accurate tumour
taging. Theselective increase in tumour tissueuptakeof anticancer
gents would be of great interest in cancer chemotherapy, because
nticancer drugs are not speciﬁc to cancer cells (Hu et al., 2006).
outes of administration, biodistribution, and elimination of avail-
ble chemotherapeutic agents can be modiﬁed by drug delivery
ystems in order to optimize the cancer therapy. Conventional can-
er therapy and diagnostics involve the application of catheters,
urgery, biopsy, chemotherapy, and radiation. Most current anti-
ancer agents do not greatly differentiate between cancerous and
ormal cells. This leads to systemic toxicity and adverse effects.
onsequently, the systemic application of these drugs often causes
evere side effects in other tissues (e.g., bone marrow suppres-
ion, cardiomyopathy, and neurotoxicity), which greatly limits the
aximal allowable dose of the drug. In addition, rapid elimination
nd widespread distribution into non-targeted organs and tissues
equires the administration of a drug in large quantities, which
s uneconomical and is often complicated because of non-speciﬁc
oxicity.
New therapeutic systems for neurodegenerative illness/pain are
nder research. Because they are chronic illnesses, it is desirable
o develop new materials in order to prolong the delivery time
nd to reduce the drawbacks of the typical application systems
uch as chemotherapy (Häfeli et al., 1997). The most accurate
ethod for evaluating tumour spread is still lymph node resec-
ion and histopathological examination of each individual lymph
ode. However, this technique is too invasive for routine use. Thus,
ymphnode is clinicallyperformedbynon-invasive imagingmodal-
ties like ultrasound (US), computer tomography (CT) or resonance
omography (MRT).
In the search for an efﬁcient method for cancer ther-
py, biocompatible-based magnetic systems have been proposed
Gupta and Hung, 1989). Ideally, such materials bear on their sur-
ace or in their bulk an anticancer drug that can be driven to thef Pharmaceutics 403 (2011) 139–161
target organ and released there (Chen et al., 2009). The main dis-
advantage with drug targeting to other sites in the human body is
the rapid uptake of intravenously injected particulate drug carriers
by the mononuclear phagocyte system (Hu et al., 2006).
The ﬁrst evidence for the utility of magnetic nanoparticles in
cancer treatment was demonstrated in the early 1980s, when
Widder et al. (1979, 1983) showed signiﬁcant remission of Yoshida
sarcoma without drug toxicity in rats using magnetically targeted
albumin microspheres with doxorubicin. Some other drugs for
cancer therapy, such as Mitoxantrone, mitomycin C, etoposide,
paclitaxel, oxaliplatin and epirubicin have been bound to iron oxide
or Fe-C ﬂuids for magnetically targeted cancer treatment (Widder
et al., 1979, 1983; Bergemann et al., 1999; Goodwin et al., 1999;
Lübbe et al., 1999; Johnson et al., 2002).
It is also important to remember that the multidrug resistance
(MDR) is the primary cause for almost 90% of cancer treatment
failures (Kohler et al., 2005). Cancer cells are becoming resis-
tant to the cytotoxic effects of a wide range of structurally and
mechanistically unrelated anticancer drugs. It is known that var-
ious molecular mechanisms can contribute to reduce this effect.
Some agents confers cancer cells the strongest resistance to the
widest variety of compounds. In this ﬁeld, Chen et al. (2008) devel-
oped tetraheptylammonium-capped Fe3O4 in order to facilitate the
accumulation of daunorubicin (DNR) inside leukemia K562/A02
cells and to enhance the response of DNR in leukemia K562/A02
cells in vitro. It was demonstrated that DNR-loaded Fe3O4 have
shownhigher activity than those ofDNRalone. The cytotoxicity test
in vitro revealed that the MNPs exhibit excellent biocompatibility.
More recently, Chen et al. (2009) demonstrated that DNR-loaded
Fe3O4 particles are able to reverse leukemic K562-n/VCR cells
in vivo by inducing apoptosis. However, the system failed in the
enhancement of the cytotoxicity response in sensitive leukemic
K562-n cells in vivo.
Nanotechnology could offer a less invasive alternative, enhanc-
ing the life expectancy and quality of life of the individual with
cancer. The diameter of human cells spans from 10 to 20m.
The size of cell organelles ranges from a few nanometers to a
few hundred nanometers. Nanoscale devices can interact with
biomolecules on the cell surface and within the cells in a non-
invasivemanner, leaving the behaviour andbiochemical properties
of those molecules intact (Kim et al., 2003a,b). In this sense, macro-
molecular compounds composed by a polymer backbone loaded
paramagnetic or superparamagnetic iron oxide nanoparticles can
be used such as contrast agents. The biodistribution of these sys-
tems to different organs and tumours depends on the composition
of the lipid bilayer, substances bound to it, such as antibodies, and
the preparation method of the material, which inﬂuences the par-
ticle surface and size. In this way, there is a diversity of possible
variations of materials to synthesize and consequently, a previous
study is required to examine their accumulation behaviour in the
tumour and to choose that best adapted to the application.
5.4. Hyperthermia
The use of hyperthermia (heat) in the treatment of malignant
tumours is as old as medicine itself. Magnetic induction hyper-
thermia, one of the therapies for cancer treatment, means the
exposition of cancer tissues to an alternating magnetic ﬁeld (Häfeli
et al., 1997). The idea of hyperthermia has been recognized as a use-
ful therapeutic modality for treating malignant tumours, leading
to the possibility to kill cancer, not with drugs, but with targeted
nanoscale heaters that would essentially cook malignant cells to
death (Gazeau et al., 2008). Hyperthermia has thus been suggested
as a non-invasive and non-toxic method of inducing gene expres-
sion locally using a thermo inducible promoter (Walther et al.,
2002).
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In this context, intracellular hyperthermia methods have been
uggested and developed using MNPs, whereby the particles are
oncentrated at the tumour site and they are remotely heated using
n applied magnetic ﬁeld in order to achieve the required hyper-
hermic temperatures (42–45 ◦C) (Masashige, 2002; Fortin et al.,
008). It is known that when MNPs are injected into an organ with
tumour, they tend to accumulate in the tumourdue to theunorga-
ized vasculature, thus effectively heating the tumour as opposed
o the surrounding healthy tissue (Berry, 2009). Moreover, if they
re subjected to a variable magnetic ﬁeld, some heat is generated
ue to magnetic hysteresis loss. The amount of heat generated
epends on the nature of magnetic material and of magnetic ﬁeld
arameters. Direct injection into solid tumours, followed by expo-
ure to an alternating magnetic ﬁeld, has been shown to be capable
f inducing tumour regression (Ito et al., 2004). Cancer cells are
estroyed at temperatures higher than 43 ◦C, whereas the normal
ells can survive at these temperatures (Häfeli et al., 1997).
There are many works in the literature describing the use
f magnetic particles for hyperthermia in order to manifest a
herapeutic effect onseveral typesof tumoursbyperformingexper-
ments with animals (Luderer et al., 1993) or using cancerous cell
ultures (Chan et al., 1993). Recent studies have highlighted the
otential of MNPs in human cancer models, such as breast can-
er,whereby 10–30nm iron oxide particleswere heated effectively
Jin and Kang, 2007). Recently, Johannsen et al. (2007) published
he ﬁrst clinical experiences with MNP-mediated thermotherapy
n prostate carcinoma. Wust et al. (2006) studied the effect of the
ssociationofhyperthermiaandMNPson the toleranceof intestinal
umours.
. Concluding remarks and perspectives
Stimuli-sensitive polymers have been known for over 40 years.
owever, they still remain a subject of vigorous investigation, both
n academic and in industry ﬁelds. Thus, they can be expected to
esult in valuable applications in the near future. There are numer-
us reasons for this continuing interest. However, it is difﬁcult to
oresee in detail the potential applications of systems that rely
n stimuli-sensitive polymers. The development of devices based
pon thesematerials calls for a ﬁne-tuning of their properties. They
hould respond to the external stimuli in a way that precisely ﬁts
he application proposed. In order to achieve this approach, a bet-
er understanding of the relations between the polymer properties
dependence of behaviour at the transition point upon external
onditions) and the structure of the macromolecules is necessary.
ertainly their application in biology, medicine and other related
ciences is already obvious and will be further developed. Diagno-
is tools, intelligent carriers of drugs and prodrugs, and devices for
elivery of active species triggered by external stimuli are just a
ew examples. However, the biomedical area is not likely to remain
he only ﬁeld of potential application. Nanosensors, nanoactuators
e.g. self-controllednanovalves) and stimuli sensitive electrochem-
cal and electro-optical devices will remain objects of studies that
ill lead to numerous potential applications.
The concept of drug delivery using magnetic nanoparticles
reatly beneﬁt from the fact that nanotechnology has developed
o a stage that it makes possible not only to produce magnetic
anoparticles in a very narrow size distribution range with super-
aramagnetic properties but also to engineer particle surfaces to
rovide site-speciﬁc delivery of drugs. Due to its strong mag-
etic properties magnetite was used ﬁrst in biology and then in
edicine for the magnetic separation of biological products and
ells as well as magnetic guidance of particle systems for site-
peciﬁc drug delivery. The size, charge, and surface chemistry of
agnetic particles could strongly inﬂuence their biodistribution.f Pharmaceutics 403 (2011) 139–161 157
Another important point is that the magnetic properties depend
strongly on the size of the magnetic particles. In the last decade,
the activities in the clinical applications of magnetic carriers and
magnetic particles have been very high, due to the demand for bet-
ter diagnostic procedures as well as better treatment modalities.
Precise delivery of anti-inﬂammatory drugs to the exact area of
inﬂammation is a desirable task, since it can reduces drug dosages,
eliminates side effects on the other healthy tissues and increases
rapidity the drug action. Application of external magnetic ﬁeld to
the area of inﬂammation may provide an important enhancement
of such treatments.
Magnetic nanoparticles are rapidly becoming an important and
indispensable tool for the non-invasive study of biologic process
with MRI. The development of very small stable preparations, the
understanding of the underlying relaxation mechanisms, and the
clinical use are all factors that increase the use of magnetic carriers
in MRI. Therefore, successful development in this area will aid the
growth of the biomedical industry as well as improving the quality
of life of thepopulation. Themaindemandsonmagnetic radioactive
systems for this purpose are biocompatibility and biodegradability,
a highmagnetic susceptibility for an effectivemagnetic enrichment
in the target area and a high circulation time in the blood to allow
for the enrichment process and the extracorporeal removal of the
materials. The applied particles should have a small size distribu-
tion, uniform surface properties and to present a good colloidal
stability.
There are many publications about the utilization of the mag-
netic polymer based nanoparticles, but most of this literature can
only be used for in vitro applications, not in vivo. For this last
purpose, the polymeric matrix needs to be composed of a biocom-
patible polymer as coating agent for para- and superparamagnetic
particles. Using this concept, associated with the knowledge of
the magnetic properties of iron oxide nanoparticles, it is possible
to develop new materials able to make possible monitoring the
kinetics and biodistribution of themedication in the organismnon-
invasively using MRI as to promote a local drug delivery using the
sensitive properties of the polymer and, thus, preserving most of
the healthy tissues and cells.
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